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ABSTRACT 
Susannah S. Lewis (Ph.D., Psychology and Neuroscience) 
The role of toll-like receptor 4 in pain due to glucuronidated metabolites and neuropathic 
pain. 
Directed by Dr. Linda R. Watkins, Department of Psychology and Neuroscience, 
University of Colorado at Boulder 
 
Toll-like receptor 4 (TLR4) has recently been implicated in both chronic 
neuropathic pain and in counter-regulating morphine analgesia. The studies undertaken 
here further show the potential for TLR4 signaling activation to produce pain states.  
Specifically, a group of metabolites, glucuronide metabolites, are shown to activate TLR4 
signaling in an in vitro model and cause transient acute pain when injected intrathecally 
in small doses.  The glucuronide metabolites tested included morphine-3-glucuronide, 
ethyl glucuronide, corticosterone-21-glucuronide, estradiol-3-glucuronide, and estradiol-
17-glucuronide, as well as glucuronic acid itself.  These metabolites were previously 
considered largely non-reactive without known biological activity or toxicity at clinically 
relevant doses.  The current studies present the first evidence that they may cause TLR4-
dependent enhanced pain, which could have influence in diverse conditions such as 
morphine withdrawal hyperalgesia, hangover headache and menstrual migraine.  
Additionally, a TLR4 signaling inhibitor, (+)-naloxone was tested in neuropathic pain 
and morphine-3-glucuronide induced pain.  (+)-Naloxone does not act on opioid 
receptors, as the (-)-naloxone isomer does, but has been shown to reduce TLR4 signaling 
in vitro and in vivo. (+)-Naloxone blocked the development of pain following intrathecal 
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morphine-3-glucuronide injection, and reversed neuropathic pain in multiple models, up 
to 4 months following nerve injury.  (+)-Naloxone is a candidate small molecule, blood-
brain barrier permeable molecule for treating pain conditions where TLR4 is involved. 
Dedication 
For my mother, Huston Diehl.
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CHAPTER 1 
INTRODUCTION 
 The conventional neuron-centric view of pain processing has been significantly 
enhanced in recent years by a growing understanding of the role of glial cells and 
proinflammatory molecules in the initiation and maintenance of pain states.  This work 
has brought about novel targets for chronic pain treatment, as well as led to a better 
understanding of the mechanisms for a range of effects, including neuropathic pain and 
opioid drug action.  The studies presented here propose to further characterize a particular 
mechanism, enhanced TLR4 signaling, for proinflammatory production in the central 
nervous system and consequent enhanced pain states. 
PAIN PROCESSING 
Pain Pathways 
 The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage,” (Merskey and Bogduk, 1994).  The basic 
neural mechanisms leading to the sensation of acute pain have long been studied and are 
well understood.  Pain sensation begins with peripheral nociceptors, found on sensory 
neurons in the skin and certain internal tissues.  These peripheral nerve endings are 
stimulated by signals indicating potential tissue damage, such as hot, cold, or noxious 
chemicals.  The peripheral neurons responding to noxious stimuli are either myelinated 
Aδ fibers, or slower, unmyelinated C fibers.  Both fiber types have cell bodies in the 
dorsal root ganglia located just outside the spinal column.  Following stimulation, the 
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sensory afferents send action potentials to the dorsal horn of the spinal cord where they 
first synapse.  The dorsal horn is the first site of pain integration and modulation, and a 
focus of several of the studies presented here.  From the dorsal horn, second order 
neurons send axons up the contralateral anterolateral funiculus to the ventrobasal and 
posterior thalamic nuclei, where third order neurons then relay pain information 
ipsilaterally to the sensory cortex and other cortical areas.  Notably, the pain pathway in 
the CNS has numerous redundancies that make it very difficult to completely cut off pain 
sensation. 
 Within the dorsal horn of the spinal cord, a key region for the studies present here, 
integration and processing of pain information first takes place.  The dense grey matter of 
the dorsal horn is organized into laminae, with nociceptive neuronal cell bodies that give 
rise to the spinothalamic tract being found principally in laminae I, IV, and V.  Lamina I, 
the most superficial, receives primary sensory input from C and Aδ fibers.  These fibers 
are all glutamatergic, with a sizeable subset also releasing substance P (Todd, 2010).  
Interneurons, both excitatory and inhibitory, from Laminae I and II project to the deeper 
layers (Todd, 2010). Laminae IV and V receive input not only from pain pathways, but 
from other modalities, including touch, conveyed by Aβ fibers, and integration between 
sensory modalities as well as top-down modulation from the brain occurs (Wall, 1967).  
The presence of first order neurons from the periphery and the integrative nature of the 
dorsal horn make it a prime location for both endogenous and experimental modulation 
of the pain response. 
 
Modulation of pain processing 
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 The degree of pain elicited by a given stimulus can be altered by several neuronal 
and non-neuronal mechanisms.  Such alterations can cause an enhanced pain response to 
the same stimulus (hyperalgesia), or cause a previously nonpainful stimulus to elicit a 
pain response (allodynia).  Such conditions occur following injury and often involve 
altered activity of neurons in the dorsal horn (Woolf and Salter, 2000).  Several neuronal 
mechanisms influence the development of these states.  The brain can influence the firing 
rate of spinal neurons through top-down inhibition or enhancement of the pain response 
(Wall, 1967).  Additionally, the endogenous opioid system can reduce the amount of pain 
felt through the release of opioid peptides (Stefano et al., 2009).  Finally, several 
mechanisms, including receptor upregulation and sensitization, can result in peripheral 
and central sensory neurons becoming more responsive to stimulation (Woolf and Salter, 
2000). 
 Recently, the conventional, neuron-based view of pain modulation has been 
improved by a growing understanding of the role and function of proinflammatory 
molecules secreted by cells in the dorsal horn with innate immune abilities.  These cells 
can become stimulated to secrete proinflammatory molecules by tissue damage in the 
CNS or remotely on the peripheral nerve, pathogen invasion or the presence of an 
immunogenic molecule, a process detailed in section 2.1.  Many proinflammatory 
cytokines have neuroexcitatory effects. Interleukin-1β (IL-1), for instance, increases 
calcium conductance NMDA receptors, leading to enhanced glutamate signaling (Viviani 
et al., 2003).  Astrocytes activated by proinflammatory molecules also down-regulate 
glutamate transporters, leaving a higher concentration of glutamate in the synapse, 
enhancing signaling (Tawfik et al., 2008).  Both microglia and astrocytes secrete 
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prostaglandins and nitric oxide following proinflammatory activation, both of which can 
also enhance pain (Besson, 1999).  Proinflammatory activation in the absence of tissue 
damage has also been shown to be sufficient for pain to develop.  Intrathecal injection of 
IL-1, for instance, can induce pain when administered over the lumbar dorsal horn 
(Falchi et al., 2001). Another example is the HIV envelope protein, gp120.  When 
injected intrathecally, gp120 causes an increase in dorsal lumbar spinal cord 
proinflammatory cytokine expression and a corresponding increase in pain sensitivity 
(Milligan et al., 2001; Ledeboer et al., 2005).  These studies demonstrate that an 
immunogenic molecule, when injected intrathecally over the dorsal horn, can cause a 
sufficient spinal cord response to produce changes in pain behavior. 
 
Pathological pain states 
 Although unpleasant, pain serves an important role in alerting an organism to 
situations with the potential to damage tissues, and encouraging rest while an injury 
heals. However, in certain situations pain continues even after tissues have healed, 
becoming a pathological condition itself.  Chronic pain conditions, including neuropathic 
pain conditions, fibromyalgia, tempromandibular joint disorder, lower back pain and 
others affect millions of people. These conditions are often resistant to currently available 
treatments, making a better understanding of the mechanisms for chronic pain and the 
development of novel treatments an important priority.  The powerful opioid analgesics, 
including morphine, fentanyl, and oxycontin, can provide temporary relief but the 
development of tolerance and dependence limits their long-term effectiveness. 
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The secretion of proinflammatory molecules in the CNS, principally by microglia 
and astrocytes, is a critical component of numerous pain conditions, including bone 
cancer pain (Lan et al., 2010), pain caused by an HIV envelope protein (Milligan et al., 
2001), pain caused by the chemotherapy agent taxol (Ledeboer et al., 2007) and 
neuropathic pain following injury to peripheral nerve fibers.  The subject of a series of 
studies in this dissertation, neuropathic pain is particularly well studied with regard to the 
role of proinflammatory glial activation.  The microglial activation marker, CD11b, and 
the astrocyte activation marker, glial fibrilliary acidic protein (GFAP) are reliably 
upregulated in neuropathic pain conditions (Tsuda et al., 2003; Narita et al., 2006; 
Hutchinson et al., 2008b).  Neuropathic pain is transiently reversed by glial activation 
inhibitors, such as minocycline (Raghavendra et al., 2003), propentofylline (Tawfik et al., 
2007) and ibudilast (Ledeboer et al., 2006).  Neuropathic pain is also transiently reversed 
by blocking cytokine action, including intrathecal injection of interleukin-1 receptor 
antagonist (IL-1ra) and tumor necrosis factor alpha (TNFα) soluble factor (Sweitzer et 
al., 2001).  Given the pervasiveness of a CNS proinflammatory component to many 
different chronic pain states, developing chronic pain treatments that specifically target 
this response may prove fruitful. 
Innate immune cell types in the CNS  
 Several cell types are capable of releasing proinflammatory molecules into the 
central nervous system. Astrocytes, microglia and CNS endothelial cells, while all having 
distinct functions in healthy tissue, have each been demonstrated to secrete 
proinflammatory molecules into the CNS following activation.  The studies presented 
here focus on the proinflammatory response, utilizing study designs that are not able to 
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distinguish which of these cell type(s) are principally involved.  It is nonetheless 
important to understand the function of these cell types, which are the candidates for 
mediating the effects to be examined. 
 Resident microglia in the CNS are bone-marrow derived cells similar to 
peripheral macrophages (McKercher et al., 1996).  Microglia are the principal 
phagocytotic cell in the CNS that responds to damaged or apoptotic cells.  They have 
many branches, each covered with receptors, including toll-like receptors, ATP receptors 
and neurotransmitter receptors that detect changes to their local environment in the CNS 
indicative of danger or pathogen invasion (Ransohoff and Perry, 2009).  Following 
detection of a change to their environment, they change morphologically, biochemically 
and functionally.  In most cases, they become activated to secrete proinflammatory 
molecules, which in turn activate other microglia and astrocytes nearby (Romero-
Sandoval et al., 2008).  In select circumstances, however, they can become alternatively 
activated, secreting instead anti-inflammatory molecules, such as IL-4 and IL-13 and/or 
reducing their secretion of proinflammatory cytokines (Ponomarev et al., 2007).  
 Astrocytes shelter nearly every synapse in the brain.  They have glutamate 
receptors, which take up excess neurotransmitter following synaptic transmission, and in 
this respect have the ability to directly influence neuronal signaling (Parpura et al., 1994).  
Like microglia, they also have receptors that respond to changes in their 
microenvironment and can mount a proinflammatory response in addition to increasing 
the level of glutamate in the synaptic cleft (Dong and Benveniste, 2001). 
 Endothelial cells are a critical component to the blood-brain barrier. These 
polarized cells form tight junctions, creating the capillaries throughout the CNS.  These 
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cells have one pole on the blood side and the other on the brain side and as such, have 
access to both the blood and the CNS (Persidsky et al., 2006).  Endothelial cells also 
express several cell surface receptors for danger signals, including toll-like receptors, and 
can secrete proinflammatory cytokines following receptor signaling (Ransohoff and 
Perry, 2009; Nagyoszi et al., 2010).  Additionally, following proinflammatory 
stimulation, endothelial cells can become ‘leaky’, allowing blood components, including 
limited numbers of monocytes, into the CNS (Persidsky et al., 1999).    
 
TOLL-LIKE RECEPTOR 4 (TLR4) IN THE CENTRAL NERVOUS SYSTEM 
TLR4 
Many potential mechanisms for initiating proinflammatory glial cell activation 
have been proposed, including P2X4 ATP receptors (Tsuda et al., 2003), TLR3 (Obata et 
al., 2008), and fractalkine receptors (CX3CR1) (Milligan et al., 2004b).  The mechanism 
of particular interest to the present body of work is the innate immune toll-like receptor 4 
(TLR4).  TLR4 is a highly conserved, transmembrane pattern recognition receptor that 
detects molecular patterns associated with pathogen invasion or tissue damage.  TLR4 
has been detected in the central nervous system on microglia (Bsibsi et al., 2002), CNS 
endothelial cells (Nagyoszi et al., 2010), astrocytes (Gorina et al., 2011) and, in particular 
circumstances following ischemic injury, neurons as well (Tang et al., 2007). 
Behaviorally, TLR4 signaling has been linked to such diverse conditions as enhanced 
pain (discussed in detail in section 2.3), tissue reperfusion injury following cortical 
ischemic insult (Tang et al., 2007; Arslan et al., 2010) and amyotrophic lateral sclerosis 
(Casula et al., 2011). 
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 TLR4 signaling is best understood with regard to its classic agonist, 
lipopolysaccharide (LPS), a component of gram negative bacterial cell walls (for review, 
(Dauphinee and Karsan, 2006).  In summary, TLR4 activation requires several co-
receptors and extracellular factors, including CD14, MD-2, and LPS binding protein, to 
be brought together on a lipid raft in the cell membrane.  Intracelluarly, two convergent 
signaling cascades are involved, the first, and most utilized, is the MyD88-dependent 
pathway and the second, the slower MyD88-independent pathway.  Ultimately, these 
signaling pathways result in the activation of several kinases and transcription factors.  
The transcription factor NFκB is activated through either TRAF6 or PI3K/akt signaling.  
The mitogen-activated protein kinases, including ERK and JNK, are phosphorylated 
leading to the activation of the transcription factor AP-1.  In a carefully regulated 
orchestration of these multiple pathways, TLR4 activation can lead to an increase in 
proinflammatory signaling, a pro- or anti-apoptotic state, or cell growth, depending on 
exact conditions.  The complexity of the signaling pathways leads to many potential 
targets for manipulation. 
 
TLR4 in neuropathic pain 
 TLR4 signaling has been linked to enhanced pain states. Either TLR4 (Tanga et 
al., 2005) or co-signaling molecule CD14 (Cao et al., 2009) knockout mice developed 
reduced neuropathic pain compared to wild type.  Additionally, competitive TLR4 
antagonists, including LPS from Rhodobacter sphaeroides and mutant LPS, have been 
shown to transiently reverse established neuropathic pain following chronic constriction 
injury (Hutchinson et al., 2008b).  In a rat model of bone cancer pain, pain behavior was 
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attenuated when TLR4 expression was reduced with siRNA (Lan et al., 2010), and TLR4 
siRNA has also been shown to reduce the development of neuropathic pain (Wu et al., 
2010).  A novel compound for TLR4 signaling inhibition is naloxone.  Both the opioid-
active (-)- and opioid-inactive (+)-naloxone isomers of naloxone have been shown to 
reduce TLR4 signaling in an in vitro model, and reduce glial activation markers and 
neuropathic pain in vitro (Hutchinson et al., 2008b).  (+)-Naloxone is a novel, blood brain 
barrier permeable, TLR4 signaling inhibitor that will also be explored throughout this 
work. 
 
TLR4 activation by exogenous drugs 
Given that TLR4 responds to a range of molecules, and that TLR4 signaling has 
been linked to pain, the question arises of whether compounds that enhance TLR4 
signaling will produce pain absent of any tissue damage.  Evidence with the classic 
agonist LPS is mixed.  Several groups have reported the development of allodynia 
following intrathecal injection of LPS (Clark et al., 2010; Saito et al., 2010).  However, 
others had difficulty replicating these findings (Hutchinson et al., 2009b)).  Given the 
complexity of the TLR4 receptor complex and intracellular signaling pathways, it may be 
that second signals are needed to bring all the necessary components together.  Certain 
models and techniques (e.g. more invasive intrathecal injection protocols) may provide 
these second signals while others do not. 
 Several classes of drugs can enhance TLR4 signaling, including opioids 
(Hutchinson et al., 2010b) and certain tricyclic antidepressents (Hutchinson et al., 2010a).  
The finding that morphine could activate TLR4 signaling raised an intriguing question: 
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what if TLR-4 signaling increased pain, the very condition morphine was trying to 
relieve? The finding that morphine could increase TLR4 signaling provided a novel 
hypothesis for certain negative side effects, including tolerance and dependence.  
Tolerance results in the need for increasing doses for the same analgesic effect, while 
dependence results in withdrawal symptoms upon drug cessation.  Traditionally, 
morphine tolerance and dependence have been viewed as a purely neuronal mechanism.  
Mechanisms include mu opioid receptor desensitization or down regulation (Raehal and 
Bohn, 2005) and reduced endogenous opioid production (Stefano et al., 2009).  
More recently, however, morphine has been shown to upregulate 
proinflammatory cytokines, which counteract morphine analgesia acutely (Hutchinson et 
al., 2008a), enhance the development of morphine tolerance (Johnston et al., 2004; 
Raghavendra et al., 2004b) and contribute to morphine dependence (Hutchinson et al., 
2009a).  The finding that morphine can activate TLR4, a receptor linked to enhanced pain 
states and proinflammatory cytokine release provides a novel mechanism for these 
counter-regulatory effects.  Further, it suggests that other exogenous drugs that activate 
TLR4 may have similar side effects due to proinflammatory activation in the CNS.  Such 
a finding would provide a mechanism for improving drug effect by blocking TLR4 or 
proinflammatory cytokines, much like blocking proinflammatory cytokines enhances 
morphine analgesia (Hutchinson et al., 2008a). 
 
DRUG METABOLITES  
Drug metabolism 
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Following drug administration, most compounds are absorbed into the 
bloodstream, distributed to the tissues, metabolized into chemically altered compounds 
and, finally, excreted.  The studies here focus on the products of the metabolism portion 
of this process.  In phase I metabolism, enzymes alter the chemical structure of the parent 
compound through oxidation, reduction or hydrolysis.  For example, ethanol is oxidized 
by alcohol dehydrogenase to form acetaldehyde in phase I metabolism.  In phase II 
metabolism, enzymes conjugate the parent drug with a subgroup that alters the functional 
properties of the parent compound. These subgroups include sulfate, glucuronide and 
methyl groups and change the properties of the parent drug, often making them more 
water soluble for urinary excretion.  In many, but not all, cases, these conjugated 
compounds lose their activity at the site of action for the parent drug.  Metabolites are 
typically of interest when they either remain active at the parent drug’s site of action, or 
produce toxicity at clinically relevant dosages.  More recently, more subtle effects of 
drug metabolites have begun to be recognized as potential contributors on- and off-target 
drug effects (Fura, 2006).  These include the negative effects of the acyl glucuronides, 
discussed below. 
 
Glucuronide metabolites 
The conjugation of a glucuronide group to a parent drug is catalyzed by a family 
of enzymes, the uridine-diphosphate glucuronosyltransferases (UDP-GTs).  These 
enzymes are primarily expressed in the liver, however central nervous system expression 
has also been reported in mouse (Inoue et al., 2007), rat (Leclerc et al., 2002) and human 
(Yamada et al., 2003).  Numerous other classes of drugs are glucuronidated, including 
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opioids (Christrup, 1997), steroid hormones (Jantti et al., 2007), ethanol (Wurst et al., 
2003) and non-steroidal anti-inflammatory drugs (NSAIDs) (Regan et al., 2010). 
One intriguing finding from previous studies investigating opioid-induced TLR4 
signaling in vitro was that one of two metabolites tested, morphine-3-glucuronide, 
appeared to activate TLR4 in vitro, even more so than morphine itself (Hutchinson et al., 
2010b).  This raised a question as to whether the conjugation of a glucuronide group to 
the morphine molecule actually enhanced its TLR4 signaling ability.  Currently, the U.S. 
Food and Drug Administration (FDA) guidelines suggest that most glucuronide 
metabolites are inert and have a low risk of toxicity, and therefore are typically excluded 
from the safety testing required of other metabolite classes (Davis-Bruno and Atrakchi, 
2006).  However, such guidelines do not address the possibility of effects other than 
toxicity, which may impact the parent drug action or side effects.  The survey here of 
glucuronidated metabolites seeks to determine if any of them possess the ability to 
enhance TLR4 signaling, proinflammatory signaling and/or increase pain behaviors.   
One class of glucuronide metabolites specifically excluded from FDA guideline 
labeling most glucuronide metabolites as low risk are the acyl glucuronides.  Acyl 
glucuronides are formed from the conjugation of numerous common, carboxylic acid-
based drugs, including several NSAIDs, such as naproxen and ibuprofen, and the diuretic 
furosemide (Regan et al., 2010).  These drugs are known to produce adverse drug effects 
in rare cases, including hypersensitivity and hepatitis (Regan et al., 2010). Although the 
mechanism of action for the adverse effects of acyl glucuronides is currently unknown, it 
has been proposed that protein adducts form, causing an immunogenic response (Regan 
et al., 2010).  Unfortunately, none of these glucuronidated compounds were available 
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commercially and remain to be investigated.  Nonetheless, the acyl glucuronides present 
a case of glucuronide metabolite that can cause an immunogenic response and adverse 
drug reactions.  Other studies of glucuronide metabolites have viewed them as a 
deactivating step, as they commonly lose activity at the site of parent drug action.  For 
instance, estradiol glucuronide conjugation is viewed as a positive step that reduces the 
estrogens available to estrogen-sensitive breast tumors (Guillemette et al., 2004).  
Notably, no systematic exploration of potential for enhanced pain or immune receptor 
activation of any of these metabolites has been undertaken previously.  
  
PURPOSE OF STUDIES 
 The studies here explore the role of TLR4 in enhanced pain states.  The potential 
of glucuronide metabolites to activate TLR4 and produce pain sensitization will be tested.  
Specifically, the potential of morphine-3-glucuronide, glucuronic acid, ethyl glucuronide, 
estradiol-3-glucuronide, estradiol-17-glucuronide and corticosterone-21-glucuronide will 
be investigated.  Additionally, the role of TLR4 in ongoing neuropathic pain will be 
further investigated, expanding on the potential of (+)-naloxone as a TLR4 inhibitor, 
initially reported in Hutchinson et al. (2008).  These studies aim to, in total, further 
explore the potential for TLR4 involvement in pain states. 
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ABSTRACT 
 
Morphine-3-glucoronide (M3G) is a major morphine metabolite detected in 
cerebrospinal fluid of humans receiving systemic morphine.  M3G has little-to-no affinity 
for opioid receptors and induces pain by unknown mechanisms.  The pain-enhancing 
effects of M3G have been proposed to significantly and progressively oppose morphine 
analgesia as metabolism ensues.  We have recently documented that morphine activates 
toll-like receptor-4 (TLR4), beyond its classical actions on µ-opioid receptors. This 
suggests that M3G may similarly activate TLR4.  This activation could provide a novel 
mechanism for M3G-mediated pain enhancement, as (a) TLR4 is predominantly 
expressed by microglia in spinal cord and (b) TLR4 activation releases pain-enhancing 
substances, including interleukin-1 (IL1). We present in vitro evidence that M3G 
activates TLR4, an effect blocked by TLR4 inhibitors, and that M3G activates microglia 
to produce IL1. In vivo, intrathecal M3G (0.75 µg) induced potent allodynia and 
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hyperalgesia, blocked or reversed by interleukin-1 receptor antagonist, minocycline 
(microglial inhibitor), and (+)- and (-)-naloxone. This latter study extends our prior 
demonstrations that TLR4 signaling is inhibited by naloxone nonstereoselectively. These 
results with (+)- and (-)-naloxone also demonstrate that the effects cannot be accounted 
for by actions at classical, stereoselective opioid receptors.  Hyperalgesia (allodynia was 
not tested) and in vitro M3G-induced TLR4 signaling were both blocked by 17-DMAG, 
an inhibitor of heat shock protein 90 (HSP90) that can contribute to TLR4 signaling. 
Providing further evidence of proinflammatory activation, M3G upregulated TLR4 and 
CD11b (microglial/macrophage activation marker) mRNAs in dorsal spinal cord as well 
as IL1 protein in the lumbosacral cerebrospinal fluid.  Finally, in silico and in vivo data 
support that the glucuronic acid moiety is capable of inducing TLR4/MD-2 activation and 
enhanced pain.  These data provide the first evidence for a TLR4 and IL1 mediated 
component to M3G-induced effects, likely of at least microglial origin. 
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The neuroactive metabolites of morphine can contribute to its effects.  Morphine 
is principally metabolized in the liver, but is also metabolized in the central nervous 
system (CNS) (King et al., 1999).  In humans, ~44-55% of morphine is metabolized to 
morphine-3-glucuronide (M3G), 9-15% to morphine-6-glucuronide (M6G), 8-10% 
excreted as morphine and the remainder converted into numerous minor metabolites 
(Christrup, 1997; Andersen et al., 2003).  Clinical studies have consistently found M3G 
and M6G in the CNS following systemic morphine, including in lumbosacral 
cerebrospinal fluid (CSF) (Sjogren et al., 1998; Dale et al., 2007). 
One of the major metabolites of morphine, M6G, is a µ opioid receptor agonist 
and a more potent analgesic than morphine (Abbott and Palmour, 1988).  In contrast to 
M6G, M3G has been reported to enhance pain, although the mechanisms are unknown.  
Unlike M6G, M3G has little-to-no affinity for µ, κ, or δ opioid receptors (LaBella et al., 
1979).  To date, all studies of M3G-induced allodynia and hyperalgesia have sought 
exclusively neuronal mechanisms to explain its effects. Behaviorally, inhibited NMDA 
receptor activity or increased GABA activity can reduce the effects of M3G (Bartlett et 
al., 1994b).  However, M3G has no affinity for NMDA or GABA receptors (Bartlett et 
al., 1994a) and in vitro its effects on NMDA are not direct (Hemstapat et al., 2003).   
We propose an alternative hypothesis for M3G-induced pain enhancement, 
through M3G-induced proinflammatory responses by immunocompetent cells including 
microglia. The proinflammatory molecules released by activated microglia and other 
immunocompetent cells increase neuronal excitability, which has been shown to increase 
pain sensitivity in various pain models (Milligan and Watkins, 2009).  Studies of 
morphine indicate that a proinflammatory response opposes morphine analgesia, and 
  
17
microglial and astrocyte activation markers are upregulated following repeated morphine 
(Song and Zhao, 2001; Hutchinson et al., 2009a).  Behaviorally, blocking morphine-
induced release of proinflammatory molecules prolongs acute morphine analgesia and 
attenuates morphine-induced hyperalgesia (Johnston et al., 2004; Hutchinson et al., 
2008a). Given the structural similarity between morphine and M3G, we hypothesized that 
M3G may induce glial activation and release of proinflammatory molecules, and that this 
effect may be involved in enhanced pain in response to both M3G and morphine.   
It has largely been assumed that morphine-mediated effects on microglia and 
astrocytes were due to µ opioid receptor activity, the same mechanism as the analgesic 
effects of morphine on neurons.  However, a growing body of evidence suggests that a 
novel, non-classical opioid receptor is primarily responsible.  In contrast to morphine’s 
analgesic activity, glial activation following morphine is nonstereoselective, and there is 
a similar lack of stereoselectivity in naloxone inhibition of morphine-induced glial 
activation (Hutchinson et al., 2010b).  One candidate receptor for nonstereoselective 
morphine-induced glial activation is toll-like receptor 4 (TLR4).  TLR4 is expressed 
predominantly by microglia in the CNS and, when activated by a wide range of 
endogenous or exogenous molecules, leads to microglial activation and release of 
proinflammatory products including interleukin-1 (IL1) (Lehnardt et al., 2003).  TLR4 is 
activated by opioids in a nonstereoselective manner (Hutchinson et al., 2010b), and 
inhibited by both (+)- and (-)-naloxone (Hutchinson et al., 2008b), consistent with 
observations of morphine-induced glial activation.   
This study seeks to investigate a potential non-neuronal component to M3G-
enhanced pain.  We present evidence that inhibitors of TLR4 signaling can block M3G-
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induced TLR4 activity in vitro.  We then employ a range of pharmacological approaches 
to explore mechanisms underlying M3G-induced pain enhancement and define the effect 
of M3G on mRNA levels in the dorsal spinal cord reflective of a proinflammatory 
process. 
MATERIALS AND METHODS 
Animals 
 Adult, male, pathogen-free Sprague-Dawley rats (Harlan Labs, Madison, WI) 
were used for all in vivo experiments.  Rats (350-400 g at time of experiments) were 
housed in temperature (23±3 oC) and light (12 h:12 h light:dark) controlled rooms with 
water and food given ad libitum.  All habituation and behavioral testing procedures were 
performed during the light phase of the daily cycle.  All procedures were approved by the 
University of Colorado-Boulder Institutional Animal Care and Use Committee.  Unless 
otherwise noted, each experimental group was comprised of 6 rats. 
 
Drugs 
 M3G, minocycline, (-)-naloxone and glucuronic acid were purchased from Sigma 
(St. Louis, MO).  (+)-Naloxone was obtained from the National Institute on Drug Abuse.  
IL1 receptor antagonist (IL1ra) was purchased from Amgen (Thousand Oaks, CA).  17-
DMAG was purchased from Tocris Biosciences (Ellisville, MO).  Endotoxin-free, sterile 
0.9% saline (Abbott Laboratories, North Chicago, IL) was used as a vehicle for all drugs 
in behavioral studies (Experiments 3-6, 8).  M3G, saline, (+)-naloxone, (-)-naloxone, 
minocycline, 17-DMAG and IL1ra were confirmed to be endotoxin-free.  Where 
appropriate, doses are reported as a free base concentration. 
  
19
 All drugs administered in vivo were given intrathecally over lumbosacral spinal 
cord in Experiments 3-6, 8 and 11.  M3G was administered at a dose of 0.75 µg, based on 
pilot studies. Minocycline was administered as 2 successive doses (100 µg followed by 
33.3 µg), with the first dose prior to M3G and the second dose concurrent with M3G, as 
described in the experimental procedures below. This dosing regimen was based on 
Ledeboer et al. (2005), which showed that minocycline is more effective at blocking 
microglial activation than reversing it.  (+)-Naloxone and (-)-naloxone were given at a 
dose of 20 µg, consistent with Hutchinson et al. (2008b), which showed a significant 
reversal of neuropathic pain by this dose of (+)-naloxone. IL1ra was administered at a 
dose of 100 µg, a dose that potentiates morphine analgesia by reducing the 
proinflammatory response by glia and mitigating the neuroexcitatory effects of IL1 
(Hutchinson et al., 2008a).  In Experiment 4, a second dose of IL1ra was given 60 min 
into the 125 min time course to obviate the short half-life of IL1ra (Milligan et al., 2005).  
17-DMAG was given at 4 µg, a dose which suppresses neuropathic pain (Hutchinson et 
al., 2009b).  In Experiment 5, IL1ra and (+)-naloxone were each co-administered with 
M3G and readministered 1.5 h into the experiment due to their short half-lives. For the 
same reason, the second mechanical sensitivity testing time point was moved from 4 h to 
3 h between Experiment 3a and Experiment 5.  In Experiment 11, glucuronic acid was 
administered in equimolar concentration to the M3G dose, at a dose of 0.38 µg and (+)-
naloxone was again administered at a dose of 20 µg. 
 
Intrathecal catheter implantation and injections 
  
20
Acute intrathecal injections were used to administer drugs in Experiment 3a.  
Acute indwelling intrathecal catheters were used to administer drugs in Experiments 3b, 
4, 6 and 8.  Chronic indwelling intrathecal catheters were used in Experiments 5 and 11.  
Catheter implantations via the L5/L6 intervertebral approach and drug microinjections 
were performed based on Milligan et al. (1999). For each of the 3 procedures, rats were 
briefly anaesthetized under isoflurane anesthesia. An 18-gauge needle was placed 
between L5 and L6 into the intrathecal space and served as a guide.  Sterile polyethylene-
10 tubing was threaded rostrally through the guide so to terminate over the lumbosacral 
enlargement.  
For acute injections in Experiment 3a, the catheters were pre-loaded with drugs at 
the intrathecal end and the remainder filled with sterile saline. Upon insertion, the drug 
was injected with a 10.5 µl flush to ensure complete drug delivery, and the needle and 
catheter then removed.  
For acute indwelling lumbosacral catheters, used in Experiment 3b, 4, 6 and 8 the 
18-gauge needle was removed after catheter placement and the tubing secured to the 
superficial musculature of the lower back with 3-0 silk suture.  The tubing was then 
threaded subcutaneously to exit the nape of the neck. Catheters were 90 cm in length, 
pre-loaded with drugs at the intrathecal end and the remainder filled with sterile saline.  
This allowed remote injection of drug during behavioral testing without disturbing the 
animal, and the injection of a small void volume (10.5 µl) that ensured delivery of drugs.  
Drug administration occurred 2 h after intrathecal catheter placement. 
Chronic indwelling lumbosacral catheters used in Experiment 5 and 11 were 45 
cm in length and heat sealed at the external end until used for drug injections. Rats were 
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allowed to recover from this catheter placement for 7 d before behavioral testing and drug 
administration.  Catheters were filled with sterile saline and the appropriate drug dose in 
1 µl, followed by 3 µl of saline.  Injections had a total volume of 50 µl, due to the void 
volume of the catheter that preceded the drug into the intrathecal space.   
 
Behavioral Testing 
 All testing was conducted by an experimenter blind to group assignment.  
Separate rats were used for assessing thermal and mechanical response thresholds.  Rats 
received at least four 1 h habituations to the appropriate testing apparatus and 
environment prior to baseline testing, as in our previous studies (Hutchinson et al., 
2008b). There were six rats in each experimental group. 
 
Hargreaves test for thermal hyperalgesia 
 Thermal testing measured withdrawal latency to radiant heat applied separately to 
the tail and the plantar surface of each hind paw in a modified Hargreaves test 
(Hargreaves et al., 1988).  Baseline latencies prior to drug administration were calculated 
as the average of two latencies, measured 15 min apart.  Following drug administration, 
latencies to withdrawal from each paw and the tail were measured at 10 min intervals for 
125 min.  The intensity of the heat source was adjusted such that pre-drug latencies to 
withdrawal were 8-10 s, with a 20 s cut off to avoid tissue damage. This allowed both 
analgesia and hyperalgesia to be measured.  The percent maximum possible effect 
(%MPE) was calculated for each testing point from each rat as: %MPE=[test latency-
baseline latency]/[cut-off – baseline latency] x100. 
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von Frey test for low threshold mechanical allodynia 
 The response threshold to light touch on both hind paws was measured using 
calibrated microfilaments (von Frey hairs; Stoelting, Wood Dale, IL, USA), as described 
in Milligan et al. (2000).  Briefly, a logarithmic range of hairs from 0.406-15.136 g force 
were used, allowing both analgesia and allodynia to be measured, following the standard 
up-down procedures previously described (Chaplan et al., 1994). Baseline thresholds 
were taken as the average of two tests from each paw.  Responses were fitted to a 
Gaussian integral psychometric function using a maximum-likelihood fitting method as 
described in Milligan et al. (2000).   
 
Cellular and Molecular Analyses 
In vitro assay for TLR4 signaling 
A human embryonic kidney-293 (HEK 293) cell line was used that was stably 
transfected by Invivogen to over-express human TLR4 and co-receptor molecules (MD-
2, CD14)  (293-htlr4a-md2cd14; here referred to as HEK-TLR4). In addition, these cells 
stably express an optimized alkaline phosphatase reporter gene under the control of a 
promoter inducible by transcription factors, such as NF-κB and AP-1, activated as part of 
the TLR4 signaling cascade. Secreted alkaline phosphatase (SEAP) protein is produced 
as a consequence of TLR4 activation.  
HEK-TLR4 cells were grown at 37 oC (5% CO2; VWR incubator model 2300) in 10 
cm dishes (Greiner Bio-One, CellStar 632171; Monroe, NC, USA) in normal supplement 
selection media (DMEM  media [Invitrogen, Carlsbad, CA, USA] supplemented with 
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10% fetal bovine serum [Hyclone; Logan, UT, USA], HEK-TLR4 selection [Invivogen]; 
Penicillin 10,000 U/ml [Invitrogen]; streptomycin 10 mg/ml [Invitrogen], Normocine 
[Invivogen], and 200 nM L-Glutamine [Invitrogen]).  The cells were then plated for 48 h 
in 96 well plates (Microtest 96 well plate, flat bottom, Becton Dickinson; 5 x 103 
cells/well) with the same media. After 48 h, supernatants were removed and replaced 
with 180 µl artificial cerebrospinal fluid (sterile aCSF; 124 mM NaCl, 5 mM KCl, 0.1 
mM CaCl2 . 2H20, 3.2 mM MgCl2 . 6H20, 25 mM NaHCO3, 10 mM glucose, pH 7.4) to 
model in vivo CNS conditions.  Drugs under test were added in concentrations indicated 
and incubated for 24 h.  Supernatants (15 µl) were then collected from each well for 
immediate assay. 
SEAP levels in the supernatants were assayed using the Phospha-Light System 
(Applied Biosystems) according to the manufacturer’s instructions.  This 
chemiluminescent assay incorporates Tropix CSPD chemiluminescent substrate.  The 15 
µl test samples were diluted in 45 µl of 1x dilution buffer, transferred to 96-well plates 
(Thermo, Walthma, MA, USA), and heated at 65oC in a water bath (Model 210, Fisher 
Scientific, Pittsburgh, PA, USA) for 30 min, then cooled on ice to room temperature.  
Assay buffer (50 µl/well) was added and, 5 min later, reaction buffer (50 µl/well) is 
added and allowed to incubate for 20 min at room temperature.  The light output is then 
measured in a microplate luminometer (Dynex Technologies, #IL213.1191, Chantilly, 
VA, USA). 
In vitro assay for microglial cell IL1 production 
A murine microglial cell line, BV-2 (gifted by Rona Giffard, Stanford University) 
were grown in macrophage serum free media (Invitrogen, Carlsbad, CA) in 75 cm2 
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Primaria-treated flasks (Falcon, BD Biosciences, San Jose, CA) with no supplementation 
at 5% CO2 and 37 oC. 200 000 cells/well were plated in 6-well Primaria-treated plates 
(Falcon, BD Biosciences, San Jose, CA) for 48 h, in 1.6 ml of the same media, before 
drug administration.  
Enzyme-linked Immunosorbant Assay (ELISA) for IL1 protein 
Cell lysates from BV-2 cells and CSF samples were assayed for IL1 protein 
content using commercially available mouse (BV-2 cell lysates) and rat (CSF samples) 
IL1β kits (R&D Systems, Minneapolis, MN).  Procedures were conducted according to 
manufacturer’s directions.  CSF samples were diluted 1:10 due to small sample volumes, 
as described in O’Connor et al. (2004).  The rat IL1 kit has a minimum detection 
threshold of <5 pg/ml and an inter- and intra-assay variability of <10%.   The mouse IL1 
kit had a minimum detection threshold of 6 pg/ml.  
 
mRNA isolation and real-time polymerase chain reaction (RT-PCR) quantification 
Total RNA was isolated as described in Johnston et al. (2004). Samples were 
DNase treated (DNA-free kit; Ambion), followed by cDNA synthesis. 
Amplification of cDNA was performed using the QuantiTect SYBR Green PCR Kit 
(Qiagen) in iCycler iQ 96 well PCR plates (Bio-Rad) on a MyiQ Single Color Real-Time 
PCR Detection System (Bio-Rad), as previously described (Johnston et al., 2004).  SYBR 
Green 1 fluorescence (PCR product formation) was monitored in real time using the 
MyiQ Single Color Real-Time PCR Detection System (Bio-Rad). Threshold for detection 
of PCR product was set in the log–linear phase of amplification and the threshold cycle 
(CT, the number of cycles to reach threshold of detection) was determined for each 
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reaction. The levels of the target mRNAs were quantified, using blinded procedures, 
relative to the level of the housekeeping gene β-actin using the comparative ∆∆CT 
method. In the event that an individual mRNA level was more than two standard 
deviations above the group when not included, it was considered an outlier and excluded. 
The following targets were investigated and expressed relative to the levels of the 
housekeeping gene β-actin (BC063166; forward: AGAGGCATCCTGACCCTGAA; 
reverse: GCTCATTGTAGAAAGTGTGGT): IL1 (M98820; forward: 
GAAGTCAAGACCAAAGTGG; reverse: TGAAGTCAACTATGTCCCG), Tumor 
Necrosis Factor-α (TNF) (D00475; forward: CTTCAAGGGACAAGGCTG; reverse: 
GAGGCTGACTTTCTCCTG), TLR4 (NM_019178; forward: 
CAGAGGAAGAACAAGAAGC; reverse: CCAGATGAACTGTAGCATTC), and 
CD11b (NM_012711, forward: CTGGGAGATGTGAATGGAG, reverse: 
ACTGATGCTGGCTACTGATG). Primers were purchased from Proligo (Boulder, CO, 
USA).  
 
in silico Docking simulations 
in silico Docking simulation methods previously outlined were employed to 
examine the docking of M3G and (+)-naloxone to TLR4 and MD-2 (Hutchinson et al., 
2010b).  Briefly, the complexed human TLR4 and MD-2 pdb file was obtained from 
RCSB Protein Data Bank database (PDBID: 3fxi). Modified pdb files were inputted into 
AutoDock 4.0 (http://autodock.scripps.edu), hydrogens added, and resaved in pdbqt 
format. M3G and (+)-naloxone structures were gathered using PubChem isomeric 
SMILES then converted to .pdb using a structure file generator 
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(http://cactus.nci.nih.gov/services/translate/). All dockings were executed with Lamarkian 
genetic algorithms.  
 
Statistics 
 GraphPad Prism (version 5 for Windows, San Diego, CA) software was used for 
all statistical analyses.  Two-way repeated-measures ANOVAs with Bonferroni post-hoc 
tests when appropriate were used to determine statistical significance between behavioral 
measures.  One-way ANOVAs with appropriate Bonferroni post hocs were used to 
confirm that there were no baseline differences on behavioral measures.  Independent 
sample t-tests were used to determine statistical significance on the mRNA tests.  For all 
analyses, p<0.05 was considered significant. 
 
Experimental Procedures 
Experiment 1: Can the in vitro increase in TLR4 signaling seen with M3G be blocked by 
a TLR4 antagonist? 
 M3G (10 µM) was applied to HEK-TLR4 cells as described above.  This 
concentration was determined by pilot studies to produce a robust effect without 
cytotoxicity.  Lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS, Invivogen, 
San Diego, CA) lacks functional TLR4 activity and acts as a competitive TLR4 
antagonist.  LPS-RS was applied to the HEK-TLR4 cells at the same time as the M3G at 
concentrations of 0.0, 0.01, 0.1, 1.0 ng/ml.  Cells were incubated for 24 h, then 
supernatants removed and assessed for SEAP activity, indicative of TLR4 activity. 
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Experiment 2: Does M3G induce IL1 protein in mouse BV-2 microglial cells? 
 BV-2 cells were plated in 6-well Primaria-treated plates with 200,000 cells per 
well.  After 48 h, fresh media and M3G (final concentrations of: 10 nM, 100 nM, 1 µM, 
10 µM in the well) or vehicle was added (n=6 per condition). 24 h after drug 
administration the supernatants were collected and the cells lysed in 200 µl of sonication 
buffer (cold Iscove’s culture medium containing 5% fetal calf serum and a cocktail 
enzyme inhibitor: 100 mM amino-n-caproic acid, 10 mM EDTA, 5 mM benzamidine–
HCl, and 0.2 mM phenylmethylsulfonyl fluoride). Sonicated samples were centrifuged at 
14,000 rpm at 4 °C for 10 min. Supernatants of the cell lysate and the cell culture 
supernatants were immediately measured for IL1 protein using the mouse ELISA 
described above. 
 
Experiment 3: Does M3G produce enhanced pain responses? 
 Experiment 3a: Rats received either 0.75 µg M3G or equivolume (1 µl) saline 
vehicle, via an acute intrathecal injection, as described above.  Both injections had a 
saline flush for a total injection volume of 12.5 µl. Rats were tested for mechanical 
allodynia 1 d prior to injection (baseline; BL) and again 0.75 and 4 h post-injection.   
 Experiment 3b: Drug dosing was identical to that described in Experiment 3a, 
above. Rats were tested for thermal hyperalgesia just prior to injection (BL) and again 
from 5-125 min post injection. 
 
Experiment 4: Is M3G induced hyperalgesia blocked by inflammatory and glial 
modulators? 
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 All rats received 0.75 µg M3G (in 1 µl) coadministered with one of four glial or 
inflammatory modulators or equivolume (1 µl) saline vehicle.  All injections were 
followed by a saline flush and had a total injection volume of 12.5 µl. Behavioral testing 
for thermal sensitivity occurred prior to (BL) and 5-125 min post-M3G and 
coadministered drug.  Drugs separately coadministered with M3G were: 100 µg IL1ra, 20 
µg (+)-naloxone, 20 µg (-)-naloxone, or 100 µg minocycline administered 2 h prior to 
33.3 µg minocycline coadministered with M3G as discussed above. 
 
Experiment 5: Is M3G induced allodynia blocked by inflammatory and glial modulators? 
 All rats received 0.75 µg M3G (in 1 µl) coadministered with one of 4 glial or 
inflammatory modulators or equivolume (1 µl) saline vehicle.  An additional 6 rats 
received only equivolume vehicle injections.  All injections were followed by a saline 
flush for a total volume of 50 µl. Behavioral testing for mechanical allodynia occurred 
prior to (BL), 0.75 and 3 h post-M3G and coadministered drug.  IL1ra (100 µg) was 
coadministered with M3G and again (100 µg) 1.5 h post-M3G administration due to its 
shorter half-life.  Similarly, (+)-naloxone (20 µg) and (-)-naloxone (20 µg) were both 
coadministered with M3G and administered again 1.5 h after M3G administration due to 
short half lives.  Minocycline was given 0.75 h (100 µg) prior to M3G and 
coadministered (33.3 µg) with M3G, as discussed above. 
 
Experiment 6: Is M3G induced hyperalgesia reversed by IL1ra? 
 Rats received either 0.75 µg M3G (in 1 µl) or equivolume saline vehicle, via an 
acute indwelling intrathecal injection.  Both injections had saline flush for a total 
  
29
injection volume of 12.5 µl. Behavioral testing occurred prior to (BL) and then 5-55 min 
after injection. At this time, either IL1ra or equivolume (12.5 µl) saline vehicle was 
administered, and response thresholds recorded for an additional 5-65 min post-IL1ra. 
 
Experiment 7: Does the HSP90 inhibitor 17-DMAG block M3G-induced TLR4 signaling 
in vitro?  
M3G (10 µM) was applied to HEK-TLR4 cells as described above and identical 
to the procedure for Experiment 1. This concentration of M3G was determined by pilot 
studies to produce a robust effect without cytotoxicity. 17-DMAG, a HSP90 inhibitor, 
was applied to the HEK-TLR4 cells at the same time as the M3G at concentrations of 0.0, 
0.01, 0.1, 1.0 ng/ml.  Cells were incubated for 24 h, then supernatants removed and 
assessed for SEAP activity, indicative of TLR4 activation. 
 
Experiment 8: Does the HSP90 inhibitor 17-DMAG block M3G-induced hyperalgesia? 
Rats received 0.75 µg M3G (in 1 µl) with either 4 µg 17-DMAG or equivolume (1 
µl) saline vehicle.  All injections were followed by a saline flush and had a total injection 
volume of 12.5 µl. Behavioral testing for thermal sensitivity occurred prior to (BL) and 5-
125 min post-M3G and coadministered drug. 
   
Experiment 9: Is there an increase in IL1 CSF protein level or transcription of glial 
activation markers in the dorsal spinal cord following intrathecal M3G? 
 M3G (0.75 µg, n=6) or equivolume saline vehicle (n=5) was administered via 
acute intrathecal injection, as in Experiment 3a.  While cell surface marker evidence of 
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glial activation can take 6-8 h to develop (Milligan et al., 2001) mRNA and 
proinflammatory cytokine protein expression changes can be detected much more 
rapidly, in a time frame consistent with M3G’s in vivo half-life following a single 
injection.  Sixty min after acute intrathecal M3G injection, rats were deeply anaesthetized 
with sodium pentobarbital (50 mg/kg) and lumbrosacral CSF was collected via acute 
intrathecal puncture and immediately flash frozen in liquid nitrogen.  Following CSF 
collection, rats were transcardially perfused with chilled saline.  The lumbrosacral 
enlargement of the spinal cord was exposed by laminectomy and a 1 cm section dissected 
and moved to an ice chilled glass plate.  The meninges were removed and the dorsal half 
of the spinal cord dissected.  The dorsal section was then flash frozen in liquid nitrogen.  
Samples were stored at -80 °C until RT-PCR or ELISA analysis. 
 
Experiment 10: Does M3G dock in silico the TLR4/MD-2 complex? 
 Initially, the in silico docking of ligands to the entire TLR4 MD-2 dimer complex 
was conducted (AutoGrid center set 3.438, -7.805, 2.034; 126 grid points expanding in all 
directions; GA running number of 100, Max Evals 5 × 106 and 1.0 Å spacing). These data 
demonstrated that the two ligands docked with human MD-2 independent of human 
TLR4 interactions. Therefore, all the ligands were docked to MD-2 alone with greater 
resolution (AutoGrid center set 27.991, 0.851, 19.625; 126 grid points expanding in all 
directions; GA running number of 100, Max Evals 5 × 106 and 0.375 Å spacing). The 
lowest energy and highest interaction docking conformation was visualized for (+)-
naloxone and M3G. The (+)-naloxone conformation was then saved as a combined MD-
2/(+)-naloxone pdf file and the M3G in silico docking was repeated on the new combined 
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MD-2/(+)-naloxone complex to determine the change in docking owing to the presence 
of already docked (+)-naloxone.  
 
Experiment 11: Does glucuronic acid alone induce pain behaviors and is this a TLR4-
dependent mechanism? 
 Rats received 0.38 µg glucuronic acid (in 1 µl) intrathecally, a dose equimolar to 
the M3G dose used previously, coadministered with either (+)-naloxone (20 µg in 1 µl) or 
equivolume saline.  All injections were followed by a saline flush for a total volume of 50 
µl. Behavioral testing for mechanical allodynia occurred prior to (BL), 0.75 and 3 h 
following glucuronic acid administration.  (+)-Naloxone (20 µg) was coadministered with 
glucuronic acid and administered again (20 µg) 1.5 h post-M3G administration due to its 
shorter half-life. 
 
RESULTS 
 In all studies employing the von Frey test, no differences between right and left 
hind paws were detected. Thus, results are reported as the average of the response 
thresholds recorded for both paws.  In response to the Hargreaves test, both hind paws 
and tail latencies to withdrawal showed identical patterns of results.  As consistent data 
were obtained across both hind paws and the tail, only tail flick responses are reported for 
simplicity. 
 
Experiment 1: M3G-induced TLR4 activation is blocked by a TLR4 antagonist. 
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Previous studies have shown that M3G increases TLR4-dependent SEAP 
expression in HEK-TLR4 cells compared to media control, an effect dose-dependently 
blocked by (+)-naloxone (Hutchinson et al., 2010b).  HEK cells with the SEAP reporter 
gene but without TLR4 overexpression did not increase SEAP expression (Hutchinson et 
al., 2010b).  Here, the M3G-induced TLR4-dependent SEAP expression was dose-
dependently suppressed by LPS-RS, a classical TLR4 competitive antagonist (F5,6= 110, 
p<0.05, Figure 2.1), providing further evidence that M3G can signal through TLR4.  
Post-hoc analyses showed that LPS-RS significantly reduced SEAP TLR4 signaling at 
concentrations of 0.01, 0.1 and 1.0 ng/ml.  LPS-RS alone, without coadministration of 
M3G, did not produce any increase in SEAP expression above media control.  
  
Figure 2.1.  M3G causes a significant increase in HEK-TLR SEAP reporter protein 
which is significantly reduced by the TLR4 antagonist LPS-RS at all three concentrations 
(F(5,6)= 110, p<0.05).  Error bars represent standard error of the mean. 
 
 
Experiment 2: Mouse BV-2 microglial cells produce IL1 in response to M3G in vitro 
Given that TLR4 is expressed on microglial cells, IL1 is an end product of TLR4 
activation, and that both activated microglial cells and IL1 can each contribute to 
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enhanced pain, we explored whether M3G could produce a proinflammatory response in 
mouse BV-2 microglial cells. These cells were stimulated with 10 µM, 1 µM, 100 nM, 10 
nm or 0 µM M3G for 24 h.  M3G dose dependently increase IL1 protein (Figure 2.2, 
F(4,25)=28.9, p<0.05).  Post-hoc test showed significant increases in IL1 protein in 
response to 10 µM (t=9.53, p<0.05) and 1 µM M3G (t=3.57, p<0.05) compared to 
vehicle.  There was no increase in IL1 protein in the cell culture supernatants, suggesting 
that IL1 is produced following M3G stimulation in vitro but not released under these 
experimental conditions. 
 
Figure 2.2.  M3G induces a significant increase in IL1 protein production in the mouse 
BV2 microglial cell line at concentrations of 10 µM and 1 µM (F(4,25)=28.89, p<0.05).  
Error bars represent standard error of the mean. 
 
Experiment 3: Intrathecal M3G induces thermal hyperalgesia & mechanical allodynia 
 To confirm that M3G induces exaggerated pain responses under our laboratory 
conditions, we examined both thermal (Hargreaves test) and mechanical (von Frey test) 
sensitivities following acute intrathecal injection of M3G compared to an equivolume 
saline injection.  On the Hargreaves test, there was no difference on baseline latencies to 
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withdrawal from radiant heat prior to drug administration (t10=0.53, p>0.05).   Following 
M3G administration, there was a rapid and reliable decrease in latencies compared to 
saline controls (Figure 2.3A, F(1,10)=43.3, p<0.05).   
On the von Frey test, there was no difference between groups on baseline 
response to calibrated pressure stimuli prior to intrathecal injection (t10=0.03, p>0.05), 
but a robust decrease in tactile thresholds in rats given M3G compared to those receiving 
saline (Figure 2.3B, F(1,10)=26.2, p<0.05).  Post-hoc analysis revealed a significant 
decrease in response threshold in rats receiving M3G compared to saline 4 h post-M3G 
administration (t10=5.78, p<0.05).   
 
Figure 2.3.  Intrathecal M3G causes the rapid onset of robust thermal hyperalgesia (A) 
and tactile allodynia (B).  Intrathecal M3G (0.75 µg) induced significant decrease in 
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withdrawal latencies from a radiant heat source (main effect of drug treatment 
F(1,10)=43.3, p<0.05, A).  The M3G group had a baseline withdrawal latency mean of 9.4 
s and the saline group had a baseline withdrawal mean of 8.9 s.  The same dose of M3G 
produced a significant increase in sensitivity to calibrated pressure stimuli 4 h following 
injection (main effect of drug treatment F(1,10)=26.2, p<0.05, B).  Error bars represent 
standard error of the mean. 
 
 
Experiment 4: M3G induced hyperalgesia is blocked by glial and inflammatory 
inhibitors. 
As Experiment 3 clearly showed that intrathecal M3G rapidly and potently 
produced hyperalgesia, the question arises as to the mechanisms underlying that effect.  
The induction of IL1 production in microglial cells in Experiment 2 suggests that 
proinflammatory microglial activation may be involved.  Here, we explore whether 
modulating glial activation or proinflammatory molecules will affect this M3G-induced 
hyperalgesia.  To investigate this, we tested a range of glial and inflammatory modulators 
to determine if they could block M3G hyperalgesia.  As detailed below, all glial 
activation and inflammatory inhibitors tested blocked M3G hyperalgesia when 
coadministered with M3G.  There were no baseline differences between any of the 
groups tested (F(5, 30)=0.67, p>0.05).  When all M3G, saline, and coadministered blocker 
groups were analyzed, there was a significant main effect of drug treatment on behavioral 
responses (F(5,30)=13.04 p<0.05).  Post-hoc analyses were used to delineate what 
treatment and time points were significantly different, as reported below.      
IL1 is a proinflammatory cytokine known to be induced by TLR4 signaling and 
upregulated in the CNS following morphine administration (Johnston et al., 2004; 
Hutchinson et al., 2008a).  Blocking the effect of IL1 with its receptor antagonist (IL1ra), 
while having no effect in the absence of morphine, increases the duration of morphine 
  
36
analgesia, suggesting that IL1-induced neuroexcitation opposes the pain-suppressive 
effects of morphine (Hutchinson et al., 2008a).  Coadministration of M3G + IL1ra 
suppressed M3G-induced hyperalgesia (Figure 2.4A).  The area under the curve was 
significantly smaller for M3G + IL1ra than M3G + saline, indicative of reduced 
hyperalgesia when IL1ra was also administered (Figure 2.4E).  Post hoc analysis showed 
the M3G + saline group had significantly faster (p<0.05) withdrawal latencies than M3G 
+ IL1ra at 15, 25, 35, and 75 min following intrathecal injection.  There were no 
significant differences between M3G + IL1ra and the saline + saline control group, 
indicative of a complete blockade of M3G induced hyperalgesia by IL1ra.   
Minocycline has been shown to reduce microglial activation, proinflammatory 
cytokines and neuropathic pain following inflammatory nerve injury and gp120-induced 
spinal glial activation (Ledeboer et al., 2005). Minocycline alone has no effect on basal 
pain thresholds (Ledeboer et al., 2005).  Coadministration of minocycline (100 µg) with 
M3G did not significantly attenuate pain behaviors (n=4, data not shown). However, a 
dosing paradigm where minocycline (100 µg) was given 2 h prior to the M3G and an 
additional 33.3 µg of minocycline successfully suppressed M3G-induced hyperalgesia 
(Figure 2.4B). This result is consistent with prior work showing that minocycline is more 
effective when given prior to the inflammatory stimulus (Ledeboer et al., 2005).  The 
area under the curve was significantly smaller for M3G + minocycline than M3G + 
saline, indicating reduced hyperalgesia when minocycline was administered along with 
the M3G (Figure 2.4E).  Post-hoc analyses showed a significant decrease in withdrawal 
latencies between M3G + saline relative to M3G + minocycline groups at every time 
point from 15-125 min following intrathecal injection.  There were no significant 
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differences in withdrawal latencies between M3G + minocycline and saline + saline 
groups, indicative of a complete blockade of M3G induced hyperalgesia by minocycline.   
(+)-Naloxone has been shown to block TLR4 signaling by the classic TLR4 
agonist LPS and by morphine in both HEK-TLR4 and RAW macrophages (Hutchinson et 
al., 2008b; Hutchinson et al., 2010b), reduce proinflammatory cytokine induction and 
glial activation following nerve injury, and reverse TLR4-dependent neuropathic pain 
(Hutchinson et al., 2008b).  Coadministration of (+)-naloxone with M3G significantly 
reduced M3G-induced hyperalgesia (Figure 2.4C). The area under the curve was 
significantly smaller for M3G + (+)-naloxone than M3G + saline (Figure 2.4E).  Post-hoc 
analysis showed a significant decrease in withdrawal latencies in the group administered 
M3G + vehicle relative to M3G + (+)-naloxone at 25, 35, 95 and 105 min following 
intrathecal injection.  No significant differences were observed between M3G 
coadministered with (+)-naloxone and saline controls, indicative of a complete blockade 
of M3G induced hyperalgesia by minocycline. 
 (-)-Naloxone is the opioid-active, clinically employed isomer of naloxone, which 
blocks the effect of opioids on classical opioid receptors.  However, M3G does not have 
any activity at those receptors (LaBella et al., 1979), so its hyperalgesic effects are not 
accounted for via such actions.  In contrast, both the (+) and (-) isomers of naloxone are 
able to block TLR4 activation and subsequent proinflammatory response with similar 
efficacy (Hutchinson et al., 2008b).  We predicted that (-)-naloxone would be similarly 
effective to (+)-naloxone in blocking M3G-induced hyperalgesia.  Coadministration of 
M3G + (-)-naloxone blocked M3G-induced hyperalgesia (Figure 2.4D).  The area under 
the curve was significantly smaller for M3G + (-)-naloxone than M3G + saline (Figure 
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2.4E).  Post-hoc analysis showed a significant decrease in withdrawal latencies in the 
group administered M3G + vehicle relative to M3G + (-)-naloxone at 15, 25, 35, 45, 55, 
65, 75, 115 and 125 min following intrathecal injection.  There were no significant 
differences between M3G coadministered with (-)-naloxone and saline controls, 
indicative of a complete blockade of M3G induced hyperalgesia by (-)-naloxone. 
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Figure 2.4.  M3G-induced hyperalgesia is blocked by several inflammatory and glial 
mediators.  Acute intrathecal M3G (0.75) coadministered with one of: IL1ra (100 µg 
coadministered with M3G, 100 µg at 65 min, baseline latency of 8.1 ± 0.33 s, A), 
minocycline (100 µg 120 min prior to M3G and 33.3 µg with M3G, baseline latency of 
8.8 ± 0.69 s, B), (+)-naloxone (20 µg, baseline latency of 8.8 ± .51 s, C), (-)-naloxone (20 
µg, baseline latency of 9.7 ± 0.90 s, D), blocks the rapid onset of M3G-induced 
hyperalgesia (main effect of drug F(5,30)=13.04 p<0.05).  Area under the curve analyses of 
these time courses showed M3G + saline had a significantly larger area under the curve 
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than saline + saline, M3G + IL1ra, M3G + minocycline, M3G + (+)-naloxone, M3G + (-
)-naloxone (F(5, 30)=13.1, p<0.05, E). Saline and M3G groups are repeated on each graph 
to facilitate visual comparisons. Error bars and ranges represent standard error of the 
mean. 
 
Experiment 5: M3G-induced allodynia is blocked by glial and inflammatory inhibitors. 
 The mechanisms of allodynia and hyperalgesia are not identical (Zimmermann, 
2001).  Given the success of glial and inflammatory modulators in reducing M3G 
induced hyperalgesia, we investigated these molecules on M3G induced allodynia. 
Rationales for the drugs selected for test are as described in Experiment 4, above. 
Coadministered IL1ra, minocycline, (+)-naloxone and (-)-naloxone were all able to block 
M3G-induced allodynia.  There were no baseline differences between any of the 
experimental groups (F(5, 28)=.33, p>0.05).  When all M3G, saline, and coadministered 
blocker groups were analyzed there was a significant main effect of drug treatment on 
behavioral responses (F(5,28)=2.73 p<0.05, Figure 2.5).  Post-hoc analyses were used to 
determine what treatments and time points were significantly different from M3G + 
saline controls, and are summarized below. 
Coadministration of IL1ra with M3G resulted in the blockade of M3G-induced 
allodynia.  Post-hoc analysis showed that M3G + IL1ra group had significantly decreased 
sensitivity to mechanical stimuli compared to M3G + saline 3 h following intrathecal 
administration, but not at 45 min following injection (Figure 2.5A).  There were no 
significant differences between M3G coadministered with IL1ra and saline controls. 
Coadministration of minocycline with M3G resulted in the blockade of M3G-
induced allodynia.  Post-hoc analysis showed that M3G + minocycline group had 
significantly decreased sensitivity to mechanical stimuli compared to M3G + saline 3 h 
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following intrathecal administration, but not at 45 min following injection (Figure 2.5B).  
There were no significant differences between M3G coadministered with minocycline 
and saline controls.   
 Coadministration of (+)-naloxone with M3G resulted in the blockade of M3G-
induced allodynia. Post-hoc analysis showed that M3G + (+)-naloxone group had 
significantly decreased sensitivity to mechanical stimuli compared to M3G + saline 3 h 
following intrathecal administration, but not at 45 min following injection (Figure 2.5C).  
There were no significant differences between M3G coadministered with  
(+)-naloxone and saline controls, indicative of a complete blockade of M3G hyperalgesia. 
 Coadministration of (-)-naloxone with M3G resulted in the blockade of M3G-
induced allodynia. Post-hoc analysis showed that M3G + (-)-naloxone group had 
significantly decreased sensitivity to mechanical stimuli compared to M3G + saline 3 h 
following intrathecal administration, but not at 45 min following injection (Figure 2.5D).  
There were no significant differences between M3G coadministered with  
(-)-naloxone and saline controls, indicative of a complete blockade of M3G hyperalgesia. 
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Figure 2.5.  M3G-induced allodynia is blocked by glial and immune mediators 
(F(5,28)=2.73 p<0.05).  Acute intrathecal M3G (0.75 µg) produced allodynia which was 
blocked by any one of: IL1ra (100 µg coadministered with M3G, 100 µg at 1.5 h, A), 
minocycline (100 µg 1 h prior to M3G, 33.3 µg with M3G, B), (+)-naloxone (20 µg 
coadministered with M3G, 20 µg at 1.5 h, C) or (-)-naloxone (20 µg coadministered with 
M3G, 20 µg at 1.5 h, D).  Saline and M3G groups are repeated on each graph to facilitate 
visual comparisons.  Error bars represent standard error of the mean. 
 
Experiment 6: IL1ra reverses established M3G hyperalgesia. 
 Given the effectiveness of IL1ra in blocking M3G induced hyperalgesia and 
allodynia, we investigated whether continuing IL1 release was necessary for the 
maintenance of M3G induced hyperalgesia.  IL1ra completely reversed established M3G 
hyperalgesia.  There were no baseline differences between M3G + vehicle, M3G + IL1ra, 
and vehicle + vehicle groups (F(2,14)=0.14, p>0.05).  There was a significant main effect 
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of drug treatment (F(2,14) = 14.81, p<0.05, Figure 2.6) and a significant interaction 
between drug treatment and time (F(2,14)= 4.71  p<0.05).  Post-hocs test showed that there 
were no significant differences between the M3G + later IL1ra and M3G + saline groups 
prior to IL1ra administration.  The M3G + later IL1ra group had significantly shorter 
withdrawal latencies prior to IL1ra administration when compared to saline at 25, 45, 55 
min following intrathecal M3G, prior to intrathecal IL1ra.  Following IL1ra 
administration 60 min after M3G administration, the M3G + IL1ra group’s withdrawal 
latencies rapidly increased to become significantly longer than M3G+saline at 65- 85 and 
105-125 min following M3G administration.  The withdrawal latencies for the M3G + 
IL1ra groups following IL1ra were indistinguishable from saline + saline withdrawal 
latencies, indicating that IL1ra was able to fully reverse M3G-induced allodynia. 
 
Figure 2.6.  Established M3G-induced hyperalgesia is reversed by IL1ra.  Intrathecal 
M3G (0.75 µg) produced hyperalgesia that was significantly reversed by intrathecal IL1ra 
(100 µg, baseline latency 9.0 ± 0.82 s) given 60 min following M3G (interaction F(2,14)= 
4.71  p<0.05).  Reversal was maintained for the remainder of the test.  Error bars and 
ranges represent the standard error of the mean. 
 
Experiment 7: M3G-induced TLR4 activity is blocked by the HSP90 inhibitor 17-DMAG 
in vitro. 
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TLR4 is activated in models of spinally mediated pain, but producing pain with 
TLR4 activation alone using LPS has been unexpectedly difficult.  Recent evidence 
suggests that HSP90 is able to function as a second signal to enhance TLR4 activation 
(Hutchinson et al., 2009b). We tested the HSP90 inhibitor, 17-DMAG, to determine if it 
would significantly reduce M3G-induced TLR4 activity in vitro.  The M3G-induced 
SEAP signal was significantly blocked by 17-DMAG, (F(3,8)= 94.6, p<0.05, Figure 2.7A).  
Post-hoc analyses showed that 17-DMAG reduced M3G-induced TLR4 activity, as 
measured by SEAP expression, at concentrations of 0.1 (t=6.34, p<0.05) and 1 ng/ml 
(t=17.8 p<0.05).  17-DMAG without M3G also reduced SEAP expression compared to 
media control (t=4.64, p<0.05), but a 2 (0 vs 1.0 ng/ml 17-DMAG) x 2 (0 vs 10 µM 
M3G) ANOVA indicated that the efficacy of 17-DMAG in reducing SEAP expression 
was greater when M3G was present.  This finding suggests that hsp90 may be involved in 
TLR4 signaling under basal conditions as well as during TLR4 activation. 
 
Experiment 8: M3G-induced hyperalgesia is blocked by the HSP90 inhibitor 17-DMAG 
Experiment 7 documented that the HSP90 inhibitor 17-DMAG was able to block 
M3G-induced TLR4 signaling in vitro.  To determine if HSP90 was involved in M3G-
induced hyperalgesia, we tested whether 17-DMAG could block M3G-induced 
hyperalgesia.  17-DMAG at this intrathecal dose was able to enhance morphine analgesia, 
presumably by removing anti-nociceptive morphine-induced glial activation, while 
having no effect on pain thresholds in the absence of morphine (Hutchinson et al., 
2009b).  Experiment 8 was run concurrently with Experiment 4 so the same control 
groups are used here. There were no significant baseline differences between M3G+ 
saline, M3G+17-DMAG and saline+saline groups prior to drug administration 
  
45
(F(2,14)=.215, p>.05).  Coadministration of the HSP90 inhibitor 17-DMAG with M3G 
resulted in a blockade of M3G-induced hyperalgesia (F(2,14)=24.28, p<0.05, Figure 2.7B). 
The area under the curve was significantly smaller for M3G + 17-DMAG than M3G + 
saline (F=23.5, p<0.05).  Post-hoc analysis showed a significant decrease in withdrawal 
latencies in the group administered M3G + vehicle compared to M3G + 17-DMAG at 15, 
25, 35, 45, 55, 65, 75, 85, 95, 105, 115 and 125 min following intrathecal injection.  
There were no significant differences between M3G coadministered with 17-DMAG and 
saline controls.  The relatively complete blockade here, compared to the partial blockade 
seen in in vitro Experiment 7 may be, at least in part, explained by the short 2-hour time 
course of behavioral measurement, rather than the 24 time point for the SEAP assay. 
 
Figure 2.7. The HSP90 inhibitor 17-DMAG significantly reduces M3G-induced TLR4 
activation, measured by SEAP activity in TLR4-HEK cells (main effect of 17-DMAG: 
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F(3,8)= 94.6, p<0.05, A).  17-DMAG alone reduced TLR4-induced SEAP signal, but the 
effect of 17-DMAG depended on whether M3G was present or absent (F(1,7) =57.1, 
p<0.05).  Intrathecal M3G (0.75 µg)-induced hyperalgesia is blocked by coadministration 
of 17-DMAG (4 µg, F(2,14)=24.28, p<0.05, baseline latency of 8.9 ± 0.36 s, B).  Error bars 
represent standard error of the mean. 
 
Experiment 9: M3G increases the levels of glial activation marker mRNAs and 
proinflammatory molecules. 
Given the success of microglial and inflammatory inhibition in blocking M3G-
induced allodynia and hyperalgesia, we examined the changes in IL1 protein expression 
in the CSF and proinflammatory and glial activation marker gene transcription in the 
dorsal spinal cord.  Our behavioral data showed a rapid onset of allodynia that can be 
blocked with IL1ra, indicative of rapid IL1 release following M3G administration.  In 
support of this, intrathecal M3G (0.75 µg) caused an increase in IL1 protein in the 
lumbrosacral CSF in rats given M3G compared to saline vehicle (t9=2.461, p<0.05, 
Figure 2.8A).   
We then analyzed dorsal spinal cord (meninges removed) 60 min after 0.75 µg 
intrathecal M3G administration for changes in mRNA expression relative to the 
housekeeping gene β-actin using RT-PCR.  There was no difference between treatment 
groups in the level of β-actin mRNA (t9= 0.66, p>0.05) 
Our behavioral data suggested that microglia were activated by M3G, and 
previous research has shown that the microglial activation marker CD11b is upregulated 
following chronic morphine administration (Hutchinson et al., 2009a).  Supporting and 
extending those results, we found a significant upregulation of CD11b mRNA 60 min 
following intrathecal M3G (t8= 2.45, p<0.05, Figure 2.8B).  TLR4 mRNA is increased 
following glial activation in both acute (Raghavendra et al., 2004a) and chronic pain 
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models (Tanga et al., 2005).  Again supporting and extending those results, here we 
found a significant increase in TLR4 mRNA 60 min following intrathecal M3G (t8= 5.44, 
p<0.05, Figure 2.8C), consistent with an increase in proinflammatory activation of glia.  
At the time point sampled, the proinflammatory cytokines IL1 and TNF showed no 
significant changes at an mRNA level between rats administered intrathecal M3G and 
those administered intrathecal saline. 
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Figure 2.8. M3G significantly upregulates IL1 protein in the CSF and the mRNA levels 
of glial activation markers in the dorsal spinal cord.  Intrathecal M3G (0.75 µg) 
significantly increased IL1 protein in the CSF (t9=2.461, p<0.05, A) and mRNA levels of 
CD11b (t8= 2.45, p<0.05, B) and TLR4 (t8= 5.44, p<0.05, C) compared to equivolume 
saline vehicle controls. Error bars represent standard error of the mean. 
 
Experiment 10: M3G docks in silico to MD-2 in a (+)-naloxone sensitive manner. 
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 Experiments 1-9 provide substantial evidence for a TLR4-dependent pro-
inflammatory response to M3G in the central nervous system. Therefore, to further 
validate these in vitro and in vivo experimental data, an in silico docking analysis was 
conducted using the recently published high-resolution crystalline structure of the dimer 
of human TLR4 and MD-2 (Park et al., 2009) and the in silico docking software suite 
AutoDock 4. In addition, the possible interaction of (+)-naloxone with M3G in silico was 
examined. Using AutoDock 4, 100 independent docking simulations were run for each 
ligand with the entire dimer of human TLR4 and MD-2.  M3G and (+)-naloxone both 
docked with the LPS binding cleft of MD-2, independent of interactions with TLR4. 
Current docking simulations have higher confidence in predicting the binding site than 
calculating the binding energies. Therefore, the in silico docking was repeated with MD-2 
alone at higher resolution (0.375 Å), M3G and (+)-naloxone docked to the same pocket 
of MD-2 (Figure 2.9). Interestingly, the glucuronic acid portion of M3G interacted 
closely with MD-2 residues F121 and F126 previously identified as important for TLR4 
activation by LPS (Teghanemt et al., 2008). When M3G was docked in silico again to 
MD-2 with (+)-naloxone already in place, M3G docking was modified substantially such 
that it no longer interacted with these pivotal MD-2 residues (Figure 2.9). 
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Figure 2.9 M3G (red) and (+)-naloxone (green) both bind to the LPS-binding pocket on 
MD-2 in an in silico model (A).  When M3G (teal) binding was modeled to a MD-2/(+)-
naloxone complex, M3G no longer interacted with the critical LPS-binding residues in 
MD-2 (B). 
 
Experiment 11: Glucuronic acid produced enhanced pain sensitivity, and that change is 
blocked by a TLR4 inhibitor. 
 Based on the results from Experiment 10, we would predict that glucuronic acid 
alone may be capable of inducing TLR4 activation, and that (+)-naloxone could block 
this effect.  To test whether the glucuronide portion of the molecule is capable of 
producing enhanced pain in vivo through TLR4-dependent processes, glucuronic acid 
(0.38 µg) was given intrathecally, coadministered with either (+)-naloxone (20 µg) or 
saline.  As discussed in Experiment 3, (+)-naloxone is the opioid-inactive isomer of 
naloxone which has been shown to block TLR4 activation.  Glucuronic acid produced 
significant allodynia 0.75 and 3 h following intrathecal injection (Figure 2.10, 
F(3,20)=4.23, p<0.05).  This allodynia was blocked by (+)-naloxone (20 µg) 3 h following 
glucuronic acid administration. 
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Figure 2.10.  Glucuronic acid causes enhanced pain which is blocked by the TLR4 
antagonist (+)-naloxone.  Intrathecal glucuronic acid (0.38 µg) produced robust allodynia 
0.75 and 3 h following administration (main effect of drug treatment F(3,20)=4.23, 
p<0.05).  Coadministered (+)-naloxone blocked that allodynia 3 h after administration. 
 
DISCUSSION  
 The present series of studies explored the mechanistic basis of hyperalgesia and 
allodynia induced by intrathecal administration of the morphine metabolite M3G.  We 
present the first evidence that M3G can activate microglial cells in vitro to induce IL1 
release, and that M3G induced pain enhancement is mediated by, at minimum, the 
proinflammatory cytokine, IL1, as IL1ra prevented and/or reversed M3G-induced 
hyperalgesia and allodynia and was increased in the CSF 60 min following intrathecal 
M3G.  Additionally, intrathecal minocycline, a compound known to inhibit activation of 
microglia and other monocyte-derived cells, prevented M3G-induced hyperalgesia and 
allodynia. TLR4, a receptor in the spinal cord principally expressed on microglia in the 
central nervous system, appears to be an important link.  First, M3G induced TLR4 
signaling in vitro, an effect which was blocked both by the TLR4 competitive antagonist, 
LPS-RS, and by inhibition of the TLR4 cosignaling molecule, HSP90 with 17-DMAG. 
Behaviorally, the recently discovered inhibitors of TLR4 signaling , (+)- and (-)-naloxone 
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(Hutchinson et al., 2008b; Hutchinson et al., 2010b), were each able to reduce M3G-
induced pain enhancement, an effect duplicated by the HSP90 inhibitor 17-DMAG.  
Providing further evidence for a proinflammatory response to M3G, mRNA for TLR4 
and the microglial/macrophage activation marker CD11b were both upregulated 60 min 
following intrathecal M3G.  Finally, in silico modeling confirmed the in vitro and in vivo 
inhibition of M3G effects by (+)-naloxone, demonstrating M3G docked to MD-2 and 
interacted closely with pivotal residues on MD-2 which may facilitate TLR4/MD-2 
signaling. Importantly, the in silico docking was (+)-naloxone sensitive agreeing with in 
vitro and in vivo data. The action of glucuronic acid alone was tested in vivo and found to 
produce marked allodynia which was also blocked by (+)-naloxone, again suggesting a 
role for TLR4. 
All previous studies of M3G have sought a direct action of M3G on neurons to 
explain its observed effects. The present study provides the first evidence that spinal 
microglia/macrophages likely contribute to the effects of M3G. Because M3G has no 
affinity for classical opioid receptors (LaBella et al., 1979), M3G must act via a different 
receptor to create pain enhancement. Our data support TLR4 as a receptor activated by 
M3G.  TLR4 is a pattern-recognition receptor that is expressed predominantly by 
peripheral and central immunocompetent cells of monocyte origin, including 
macrophages and microglia.  There is little to no evidence of TLR4 expression by spinal 
cord astrocytes, neurons, or endothelial cells under basal conditions (Miyake, 2007).  
Further, fluorescently tagged LPS binds to microglia but not to neurons (Lehnardt et al., 
2003), although neurons can express and up-regulate TLR4 in response to ischemia 
(Tang et al., 2007).  TLR4 signaling activation following complexing of the required 
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accessory molecules CD14 and MD-2, induces proinflammatory responses by 
macrophages following exposure to bacterial lipopolysaccharide (LPS) and other ‘danger 
signals’. Like macrophages, TLR4 activation on microglia induces a proinflammatory 
state, including the release of proinflammatory cytokines, such as IL1, that are well-
documented to enhance pain and neuroexcitation (Lehnardt et al., 2003; Milligan and 
Watkins, 2009). 
The present studies expand on prior work indicative of TLR4 signaling activation 
by both morphine and M3G, but not by the second major metabolite of morphine, M6G.  
In vitro studies of HEK-TLR4 cells found significant increases in TLR4-dependent 
reporter protein expression in response to (+)-morphine or (-)-morphine, compared to 
media control (Hutchinson et al., 2010b).  Intriguingly, M3G, but not M6G, also 
increased TLR4 signaling by these cells (Hutchinson et al., 2010b). These HEK-TLR4 
signaling data are consistent with in silico TLR4/MD-2 in silico docking data which 
indicate that M3G and morphine both optimally interact with the same “pocket” on the 3-
dimensional TLR4/MD-2 complex, whereas M6G does not bind there in the same fashion 
(Hutchinson et al., 2010b).  Indeed, TLR4 signaling induced by M3G in HEK-TLR4 cells 
was significantly greater than that induced by equimolar morphine (Hutchinson et al., 
2010b), suggestive that in vivo TLR4 signaling following morphine administration may 
increase as morphine is metabolized to M3G.   
The in silico and in vivo data strongly support a role for the glucuronide group in 
producing enhanced pain following M3G administration owing to the close interaction 
with two MD-2 residues previously found to be pivotal to LPS TLR4 signaling LPS 
(Teghanemt et al., 2008). The implications of TLR4 signaling activation by M3G’s 
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interaction with these and other residues in the absence of LPS deserves further 
investigation as it has implications for TLR4 signaling activation by other endogenous 
small molecules, environmental or pharmacological xenobiotics. For example, other 3-
glucuronide opioid metabolites have been shown to neuroexcitatory or pain enhancing 
properties, including hydromorphone-3-glucuronide (Wright et al., 1998) and 
normorphone-3-glucuronide (Smith and Smith, 1998).  The studies presented here would 
predict that glial and inflammatory activity could contribute to these responses.  
However, there may also be a contribution of the morphine moiety to the pain response, 
as other morphine-3 conjugates can also produce hyperactive motor behavior (LaBella et 
al., 1979) and tactile sensitivity (Yaksh et al., 1986; Yaksh and Harty, 1988). Further 
studies are necessary to fully elucidate the structure-function relationship of these 
molecules with TLR4/MD-2. 
The use of (+)-naloxone and (-)-naloxone as inhibitors of TLR4 signaling in the 
present studies is based on recent in vitro, in vivo, and in silico studies. In silico 
receptor/ligand computer modeling studies reveal that both (+)-naloxone and (-)-
naloxone dock in the same TLR2/MD-2 binding pocket as does morphine (Hutchinson et 
al., 2010b). In such computer modeling studies, activators and inhibitors of TLR4 
signaling are predicted to dock similarly, as the software does not allow for global 
conformation change. Conformational change upon agonist binding is necessary to 
facilitate signal transduction (agonism) versus inhibition (antagonism).  Notably, a 
recently solved TLR4/ligand complex crystal structure showed that activators and 
inhibitors of TLR4 signaling occupy the same binding site in the TLR4/MD-2 association 
(Park et al., 2009).  In vitro studies support that naloxone inhibits TLR4 signaling 
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nonstereoselectively as: (a) (+)-naloxone and (-)-naloxone each block LPS signaling both 
in HEK-TLR4 cells and in RAW274.7 macrophages, as does the classic TLR4 
antagonist, LPS-RS; (b) (+)-naloxone blocks morphine signaling both in HEK-TLR4 
cells and in RAW274.7 macrophages, as does the classic TLR4 antagonist, LPS-RS; and 
(c) while (+)-naloxone potentiates morphine analgesia in wild-type mice, it fails to 
potentiate morphine analgesia in TLR4 knockout mice (which do not express opioid 
receptors) (Hutchinson et al., 2008a; Hutchinson et al., 2010b). This same lack of 
stereoselectivity for naloxone actions was also observed in the blockade of M3G-induced 
hyperalgesia in the present study, consistent with a TLR4-dependent mechanism. Were 
M3G action to involve classical opioid receptors, only (-)-naloxone would antagonize the 
effect while (+)-naloxone would be ineffective, which was not the results observed.  
Thus, our findings support M3G action on a non-classical opioid receptor, found 
principally on microglia and blocked nonstereoselectively by naloxone, all of which is 
consistent with M3G action on TLR4/MD-2. 
TLR4 proinflammatory activation of microglia, however, appears to require a 
second signal in vitro and in vivo.  Very recent evidence suggests that heat shock protein 
90 (HSP90) can act as a TLR4 co-signaling molecule in vitro and in vivo, and blocking 
HSP90 function significantly increases and prolongs morphine analgesia consistent with 
the effects observed by direct TLR4 antagonism (Triantafilou et al., 2001; Hutchinson et 
al., 2009b).  To ascertain if HSP90 was needed as a second signal to facilitate M3G-
induced TLR4 activation, 17-DMAG, an HSP90 inhibitor, was tested both in vitro and in 
vivo. 17-DMAG did significantly attenuate M3G-induced TLR4 activity in vitro and was 
able to block M3G-induced hyperalgesia, suggestive of HSP90 involvement.  While 17-
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DMAG can also apparently enhance HSP70 following chronic administration, the 
direction of effects observed here following acute administration are not congruent with 
such a mechanism.  Given previous evidence for a role of HSP90 in TLR4-dependent 
signaling in vitro and in vivo, this provides another line of evidence for TLR4 
involvement in M3G-induced hyperalgesia. 
M3G induces other behaviors in addition to enhanced pain, including wet-dog 
shakes, tonic-clonic seizures, myoclonus and ataxia in rats (Bartlett et al., 1994a).  The 
mechanism(s) by which M3G induces such behaviors is not known, although several 
neuronally based mechanisms have been investigated without resolving the question.  All 
of the reported M3G-induced behaviors, including enhanced pain, are indicative of 
increased neuronal excitation.  Our data are supportive of a TLR4, IL1 and, likely, 
microglial component to the neuroexcitation leading to enhanced pain, and suggest that 
parallel investigations for other M3G-induced behaviors is warranted especially in light 
of recent advances in the epilepsy seizure literature implicating TLR4 and IL1 in 
epileptogenesis (Rodgers et al., 2009). 
M3G effects are very potent, requiring only 0.75 µg to markedly enhance pain, 
while greater doses of morphine are needed to produce analgesia (Hutchinson et al., 
2008a).  Given the presence of M3G in the CNS following morphine administration and 
the potency of M3G, the natural metabolic formation of M3G may be a significant 
endogenous counter-regulator, or opponent process, to morphine analgesia.  Recent 
research supports this possibility.  In rats, the decline in morphine analgesia following a 
single acute injection can be prolonged by an injection of IL1ra, evidence that 
proinflammatory mechanisms may reduce the analgesic actions of morphine (Hutchinson 
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et al., 2008a). In the same study, inhibiting other proinflammatory cytokines with soluble 
TNF receptor and interleukin-6 neutralizing antibody, as well as inhibiting microglia with 
minocycline enhanced and prolonged morphine analgesia (Hutchinson et al., 2008a).  
Further, blocking TLR4 activation enhances morphine analgesia in rats (Hutchinson et 
al., 2010b).  Given the evidence for M3G-induced inflammatory molecules presented 
here, it is reasonable to suspect that M3G-induced inflammation could contribute to the 
inflammatory opposition of morphine analgesia. 
 Such a conclusion would support prior work, using pharmacological modeling, 
which concluded that the time course of morphine analgesia was optimally accounted for 
only when including M3G concentrations as an anti-analgesic component (Mazoit et al., 
2007).  This study was based on the finding in humans that the analgesic profile of 
morphine does not parallel its CSF or plasma concentrations (Mazoit et al., 2007). This 
provided further evidence that active metabolites of morphine may play an important role 
in modulating morphine analgesia.  In this model, based on the results of a study of 50 
pain patients, the CSF time to maximum concentration of morphine was 30 min, while 
M6G had a time to maximum concentration of 4 h and M3G 10 h.  Analgesia was 
maximal around 4 h following i.v. morphine administration, such that analgesia is waning 
as M3G levels continue to rise (Mazoit et al., 2007).  Resolving the anti-analgesic effects 
of M3G could improve the analgesic efficacy of morphine.  As presented here, M3G and 
morphine both activate TLR4, M3G more potently, and produce proinflammatory glial 
activation that may oppose the analgesic effects of morphine.  This proinflammatory glial 
activation is effectively blocked by (+)-naloxone in rats.  Because (+)-naloxone does not 
reduce morphine’s analgesic effects, it may be an effective way to reduce TLR4 signaling 
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and consequent proinflammatory glial activation and anti-analgesia following morphine 
administration. 
In summary, converging lines of evidence support glial activation and release of 
proinflammatory molecules as necessary for M3G-induced pain behaviors.  Blocking the 
proinflammatory cytokine IL1, microglial activation, or TLR4 activity were each able to 
completely block M3G-induced allodynia and/or hyperalgesia.  Increases in mRNA 
levels of proinflammatory activation markers and production and release of IL1 by M3G 
both in vitro and in vivo further support this hypothesis.  Taken together, these data 
provide evidence for a substantial TLR4-dependent glial component to M3G-induced 
effects including enhanced pain and gene activation and suggest that the clinical efficacy 
of opioids for pain control could be enhanced by selectively blocking TLR4 activation by 
drugs like (+)-naloxone. 
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ABSTRACT 
 We have previously observed that the non-opioid morphine metabolite, morphine-
3-glucuronide, enhances pain via a toll-like receptor 4 (TLR4) dependent mechanism. 
The present studies were undertaken to determine whether TLR4-dependent pain 
enhancement generalizes to other classes of glucuronide metabolites.  In silico modeling 
predicted that glucuronic acid alone and ethyl glucuronide, a minor but long-lasting 
ethanol metabolite, would dock to the same MD-2 portion of the TLR4 receptor complex 
previously characterized as the docking site for morphine-3-glucuronide.  Glucuronic 
acid, ethyl glucuronide and ethanol all caused an increase in TLR4-dependent reporter 
protein expression in a cell line transfected with TLR4 and associated co-signaling 
molecules.  Glucuronic acid-, ethyl glucuronide-, and ethanol-induced increases in TLR4 
signaling were blocked by the TLR4 antagonists LPS-RS and (+)-naloxone.  Glucuronic 
acid and ethyl glucuronide both caused allodynia following intrathecal injection in rats, 
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which was blocked by intrathecal co-administration of the TLR4 antagonist LPS-RS.  
The finding that ethyl glucuronide can cause TLR4-dependent pain could have 
implications for human conditions such as hangover headache and alcohol withdrawal 
hyperalgesia, as well as suggesting that other classes of glucuronide metabolites could 
have similar effects. 
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Many drug metabolites are considered inert byproducts, but increasing evidence 
suggests certain metabolites can have more complex effects.  For instance, morphine-3-
glucuronide, a morphine metabolite, causes pro-inflammatory responses in the CNS 
(Komatsu et al., 2009; Lewis et al., 2010a).  This response induces pain enhancement 
blocked by broad-spectrum immune inhibitors (e.g. minocycline) as well as the toll-like 
receptor 4 (TLR4) signaling inhibitor, (+)-naloxone (Lewis et al., 2010a).  These data 
raise the question of whether this TLR4-dependent pain-sensitizing effect is unique to 
morphine-3-glucuronide, or found more broadly in glucuronidated metabolites. 
The pattern recognition receptor TLR4 is present on many immune cells, 
including at least microglia in the CNS (Bsibsi et al., 2002).  TLR4 activation initiates a 
proinflammatory cascade leading to proinflammatory cytokine release (Lehnardt et al., 
2003).  TLR4 is linked to enhanced pain, including neuropathic pain (Hutchinson et al., 
2008b), and decreased morphine analgesia (Hutchinson et al., 2010b), in addition to pain 
induced by morphine-3-glucuronide (Lewis et al., 2010a).  TLR4 signaling can be 
blocked nonstereoselectively by (+)- and (-)-naloxone as well as by TLR4-inactive 
lipopolysaccharide made by Rhodobacter sphaeroides (Hutchinson et al., 2008b; 
Hutchinson et al., 2010b). 
Several classes of commonly abused drugs have also been linked to increased 
TLR4 activity.  TLR4 inhibition reduces the rewarding affects of morphine and cocaine 
(Northcutt et al., 2011), and reduces sedative and ataxic effects of ethanol (EtOH) (Wu et 
al., 2011).  Additionally, TLR4 knockout mice display reduced ethanol-induced 
neuroinflammatory damage following chronic alcohol feeding (Pascual et al., 2011) and 
cultured microglia showed TLR4-dependent increases in pro-inflammatory cytokines in 
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response to EtOH (Fernandez-Lizarbe et al., 2009).  Intriguingly, none of these studies 
considered the metabolism of the drugs, leaving the potential that glucuronide or other 
metabolites could have contributed. 
EtOH is primarily metabolized by conversion to acetaldehyde in the liver.  Ethyl-
β-D-glucuronide (EtG) is a minor ethanol metabolite with about 0.04% of an EtOH dose 
excreted as EtG (Goll et al., 2002).  However, EtG has a much longer half-life than 
EtOH, and can be detected for up to 4 days after the elimination of EtOH from the body 
(Wurst et al., 2003).  EtG has also been measured in the brain tissue and cerebrospinal 
fluid in a human who died due to acute alcohol intoxication (Wurst et al., 1999).  
Notably, a standard alcoholic drink has about 13 g EtOH, so even minor metabolites such 
as EtG can be present at physiologically relevant concentrations following heavy 
drinking.  The inflammatory potential of EtG has not been previously investigated. 
However, the glucuronide component of the molecule, glucuronic acid (GA) alone can 
cause pain when injected intrathecally, which is blocked by the TLR4 antagonist (+)-
naloxone (Lewis et al., 2010a).  EtG is structurally quite similar to GA, leading to the 
prediction that it will have similar TLR4 agonist effects. 
 We hypothesize that the TLR4 agonist, nociceptive response to morphine-3-
glucuronide described in Lewis et al. (2010a) will generalize to other glucuronide 
molecules, namely GA and EtG.  Further, we propose that EtOH will also have TLR4 
agonist potential, as suggested by prior studies. 
 
MATERIALS AND METHODS 
Drugs   
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Ethyl glucuronide (EtG) was purchased from Aurora Analytics (Baltimore, MD) 
and ethyl alcohol (EtOH) from Pharmco (Brookfield, CT).  Sodium glucuronic acid (GA) 
was purchased from Sigma (St. Louis, MO).  LPS-RS was purchased from Invivogen 
(Thousand Oaks, CA) and (+)-naloxone was obtained from the National Institute on Drug 
Abuse.  Endotoxin-free sterile water (Hospira, Lake Forest, IL) was used as a vehicle for 
all drugs in vitro (Experiment 2).  Endotoxin-free, sterile 0.9% saline (Hospira, Lake 
Forest, IL) was used as a vehicle for all drugs in behavioral studies (Experiment 3).  GA, 
EtG, EtOH, (+)-naloxone, saline and water were confirmed to be endotoxin-free by the 
limulus amebocyte lysate assay (Lonza, Walkersville, MD) conducted per manufacturers 
instructions.  Where appropriate, doses are reported as a free base concentration. 
In silico docking simulations 
In silico docking simulation methods were identical to those previously described 
in detail (Hutchinson et al., 2010b). These methods were employed to examine the 
docking of glucuonic acid (GA), ethyl glucuronide (EtG), and ethyl alcohol (EtOH) to the 
TLR4/MD-2 complex.  The in silico docking analysis conducted in Experiment 1 used 
the recently published high-resolution crystalline structure of the dimer of human TLR4 
and MD-2 (Park et al., 2009) and the in silico docking software suite AutoDock 4.  
Briefly, the complexed human TLR4 and MD-2 pdb file was obtained from RCSB 
Protein Data Bank database (PDBID: 3fxi). Modified pdb files were inputted into 
AutoDock 4.0 (http://autodock.scripps.edu), hydrogens added, and resaved in pdbqt 
format. GA and EtG structures were gathered using PubChem isomeric SMILES then 
converted to .pdb using a structure file generator 
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(http://cactus.nci.nih.gov/services/translate/). All dockings were executed with Lamarkian 
genetic algorithms.  
 
In vitro assay for TLR4 signaling 
A human embryonic kidney-293 (HEK 293) cell line was used in Experiment 2. 
This cell line was stably transfected by Invivogen (San Deigo, CA) to over-express 
human TLR4 and co-receptor molecules (MD-2, CD14) (293-htlr4a-md2cd14; referred to 
here as HEK-TLR4). In addition, these cells stably express an optimized alkaline 
phosphatase reporter gene under the control of a promoter inducible by transcription 
factors, such as NFκB and AP-1, activated as part of the TLR4 signaling cascade. 
Secreted alkaline phosphatase (SEAP) protein is produced as a consequence of TLR4 
activation.  
HEK-TLR4 cells were grown at 37oC (5% CO2; VWR incubator model 2300) in 10 
cm dishes (Greiner Bio-One, CellStar 632171; Monroe, NC, USA) in normal supplement 
selection media (DMEM  media [Invitrogen, Carlsbad, CA, USA] supplemented with 
10% fetal bovine serum [Hyclone; Logan, UT, USA], HEK-TLR4 selection [Invivogen]; 
Penicillin 10,000 U/ml [Invitrogen]; streptomycin 10 mg/ml [Invitrogen], Normocine 
[Invivogen], and 200 nM L-Glutamine [Invitrogen]).  The cells were then plated for 48 h 
in 96 well plates (Microtest 96 well plate, flat bottom, Becton Dickinson; 5 x 103 
cells/well) with the same media. After 48 h, supernatants were removed and replaced 
with fresh media.  Drugs tested were added in concentrations indicated and incubated for 
24 h.  Supernatants (15 µl) were then collected from each well for immediate assay. 
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SEAP levels in the supernatants were assayed using the Phospha-Light System 
(Applied Biosystems) according to the manufacturer’s instructions.  This 
chemiluminescent assay incorporates Tropix CSPD chemiluminescent substrate.  The 15 
µl test samples were diluted in 45 µl of 1x dilution buffer, transferred to 96-well plates 
(Thermo, Walthma, MA, USA), and heated at 65oC in a water bath (Model 210, Fisher 
Scientific, Pittsburgh, PA, USA) for 30 min, then cooled on ice to room temperature.  
Assay buffer (50 µl/well) was added and, 5 min later, reaction buffer (50 µl/well) is 
added and allowed to incubate for 20 min at room temperature.  The light output is then 
measured in a microplate luminometer (Dynex Technologies, #IL213.1191, Chantilly, 
VA, USA). 
 
In vivo behavioral assessments 
 Animals. Adult, male, pathogen-free Sprague-Dawley rats (Harlan Labs, Madison, 
WI) were used for all in vivo experiments.  Rats (325-375 g at time of experiments) were 
housed in temperature (23±3 oC) and light (12 h:12 h light:dark) controlled rooms with 
water and food given ad libitum.  All habituation and behavioral testing procedures were 
performed during the light phase of the daily cycle.  All procedures were approved by the 
University of Colorado-Boulder Institutional Animal Care and Use Committee.  Each 
experimental group contains 6-8 rats. 
Intrathecal catheter implantation and injections.  All drugs administered in vivo 
in Experiment 3 were given intrathecally over lumbosacral spinal cord with acute 
intrathecal injections.  Catheter placements via the L5/L6 intervertebral approach and 
drug microinjections were performed based on Milligan et al. (1999). Rats were briefly 
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anaesthetized under isoflurane anesthesia. An 18-gauge needle was placed between L5 
and L6 into the intrathecal space and served as a guide.  Polyethylene-10 tubing was 
threaded rostrally through the guide so to terminate over the lumbosacral enlargement. 
The catheters were pre-loaded with drugs at the intrathecal end and the remainder filled 
with sterile saline. Upon insertion, the drug was injected with a 8.5 µl flush to ensure 
complete drug delivery, and the needle and catheter then removed.  The rats were 
anaesthetized for, on average, 5 minutes and had no skin incision or implantations upon 
awakening. 
GA was given at a dose of 0.32 µg, consistent with previously published data 
showing that dose was capable of inducing pain following intrathecal injection (Lewis et 
al., 2010a).  EtG was given at a dose of 0.38 µg, equimolar to the GA dose and also 
equimolar to a previously published dose of morphine-3-glucuronide that induced pain 
behaviors (Lewis et al., 2010a).  EtOH was also given equimolar to GA and EtG at 0.074 
µg.  LPS-RS was given at an intrathecal dose of 40 µg, consistent with previous literature 
showing this dose was capable of reversing neuropathic pain (Hutchinson et al., 2008b). 
 
von Frey test for tactile allodynia. All testing was conducted by an experimenter 
blind to group assignment. Rats received at least four 1 h habituations to the appropriate 
testing apparatus and environment prior to baseline testing, as in our previous studies 
(Lewis et al., 2010a). 
The response threshold to light touch on both plantar hind paws was measured 
using calibrated microfilaments (von Frey hairs; Stoelting, Wood Dale, IL, USA), as 
described in Milligan et al. (2001).  Briefly, a logarithmic range of hairs from 0.406-
15.136 g force were used, allowing both analgesia and allodynia to be measured, 
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following the standard up-down procedures previously described (Chaplan et al., 1994). 
Responses were fitted to a Gaussian integral psychometric function using a maximum-
likelihood fitting method as described in Milligan et al. (2001). 
 
Statistics 
 GraphPad Prism (version 5 for Windows, San Diego, CA) software was used for 
all statistical analyses. One-way ANOVAs with appropriate Bonferroni post hocs were 
used to compare experimental groups on in vitro experiments and to confirm that there 
were no baseline differences on behavioral measures. Two-way repeated-measures 
ANOVAs with Bonferroni post-hoc tests when appropriate were used to determine 
statistical significance between behavioral measures.  For all analyses, p<0.05 was 
considered significant. 
 
Experimental Procedures 
 
Experiment 1: Does in silico docking predict TLR4-MD2 binding of GA, EtG and/or 
EtOH?    
Initially, the in silico docking of GA and EtG to the entire TLR4 MD-2 dimer 
complex was conducted (AutoGrid center set 3.438, -7.805, 2.034; 126 grid points 
expanding in all directions; genetic algorithm running number of 100, Max Evals 5 × 106 
and 1.0 Å spacing).  Additionally, all the ligands were docked to MD-2 alone with greater 
resolution (AutoGrid center set 27.991, 0.851, 19.625; 126 grid points expanding in all 
directions; genetic algorithm running number of 100, Max Evals 5 × 106 and 0.375 Å 
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spacing). The lowest energy and highest interaction docking conformation was visualized 
and the residues on MD-2 that interacted with that conformation determined for each of 
the experimental drugs.  
 
Experiment 1B: For drugs predicted to dock to the TLR4/MD-2 complex in 
Experiment 1A, would previously docked (+)-naloxone reduce the likelihood of their 
in silico docking? 
The (+)-naloxone conformation interacting with MD-2 from a previous study 
(Lewis et al., 2010a) was saved as a combined MD-2/(+)-naloxone pdb file and the in 
silico docking was repeated on the combined MD-2/(+)-naloxone complex to determine 
the change in docking due to the presence of already docked (+)-naloxone.  
 
Experiment 2A: Does in vitro GA, EtG or EtOH cause an increase in TLR4-
dependent SEAP expression in HEK-TLR4 cells? 
 The experimental drugs, GA, EtG and EtOH, were each applied to HEK-TLR4 
cells at concentrations of 0, 1, 10 or 100 µM as described above.  Cells were incubated 
for 24 h, then supernatants removed and assessed for SEAP activity, indicative of TLR4-
induced NFκB activity. 
 
Experiment 2B: Is the in vitro increase in TLR4-dependent SEAP expression seen in 
Experiment 2A blocked by the TLR4 antagonists LPS-RS and/or (+)-naloxone? 
 For drugs which increase HEK-TLR4 SEAP production in Experiment 2A, the 
most effective dose (100 µM for each) was applied to HEK-TLR4 cells as described 
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above.  Additionally, one of two TLR4 antagonists was coadministered.  One, 
lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS, Invivogen, San Diego, CA), 
lacks functional TLR4 activity and acts as a competitive TLR4 antagonist.  LPS-RS was 
applied to the HEK-TLR4 cells at the same time as the GA, EtG or EtOH at 
concentrations of 0, 0.1, 1 or 10 ng/ml. The other, (+)-naloxone, is the opioid-inactive 
isomer of naloxone and has been shown to inhibit LPS-induced increases in HEK-TLR4 
signaling (Hutchinson et al., 2010b). (+)-Naloxone was applied to the HEK-TLR4 cells at 
the same time as the GA, EtG or EtOH at concentrations of 0, 1, 10 or 100 µM.  For all 
assays, cells were incubated for 24 h, then supernatants removed and assessed for SEAP 
activity, indicative of TLR4 activity. 
 
Experiment 3: Does intrathecal GA, EtG and/or EtOH cause tactile allodynia? Is 
that allodynia TLR4 dependent? 
Rats received either 0.32 µg GA, 0.38 µg EtG or 0.074 µg EtOH or equivolume (1 
µl) saline vehicle via an acute intrathecal injection, as described above.  Both injections 
had a saline flush for a total injection volume of 9.5 µl. Rats were tested for tactile 
allodynia 1 d prior to injection (baseline; BL) and again 1 and 3 h post-injection.   
 The drugs that produced significant allodynia (in this case, GA and EtG) were 
coadministered with the TLR4 antagonist LPS-RS.  Rats received either 0.32 µg GA or 
0.38 µg EtG or equivolume (1 µl) saline with 40 µg LPS-RS via an acute intrathecal 
injection. 
 
RESULTS 
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Experiment 1A: In silico modeling predicts that GA and EtG will bind to MD-2. 
An in silico docking study was done to determine if GA, EtG and/or EtOH would 
be predicted to dock to the TLR4/MD-2 complex and whether they interacted at the same 
residues as the TLR4 antagonist (+)-naloxone.  This in silico technique has been 
successfully used previously to model the docking of compounds, including opioids, 
morphine-3-glucuronide, and tricyclic antidepressants and to predict whether the 
compounds would act as TLR4 agonists in vitro and in vivo (Hutchinson et al., 2010a; 
Hutchinson et al., 2010b; Lewis et al., 2010a). 
The EtOH molecule was too small to be effectively modeled in this paradigm.  
The in silico docking of GA or EtG to the entire human TLR4 MD-2 dimer complex was 
initially conducted (AutoGrid center set 3.438, -7.805, 2.034; 126 grid points expanding 
in all directions; genetic algorithm running number of 100, Max Evals 5 × 106 and 1.0 Å 
spacing). These data demonstrated that the two ligands docked with human MD-2 
independent of human TLR4 interactions. Therefore, the ligands were then docked to 
MD-2 alone with greater resolution (AutoGrid center set 27.991, 0.851, 19.625; 126 grid 
points expanding in all directions; genetic algorithm running number of 100, Max Evals 5 
× 106 and 0.375 Å spacing).  The lowest energy and highest interaction docking 
conformation was visualized for GA and EtG and the residues that interacted with each 
compound determined (Table 3.1).  The residues at which lipid A chains interacted in 
previously published crystallography studies (Park et al., 2009) are also included for 
comparison on Table 3.1. 
Both GA and EtG were predicted to dock to MD-2, as demonstrated by negative 
predicted binding energies. EtG interacted at 7 residues, 6 of which were residues also 
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known to interact with the lipid A moiety of lipopolysaccharide.  GA interacted at 8 
residues on MD-2, only 1 of which was in common with lipid A interactions.  GA largely 
interacted with MD-2 at residues distant from the pockets where lipid A interacts. 
 
Experiment 1B:  (+)-naloxone alters the predicted MD-2 docking conformations of 
EtG and GA in silico. 
Given prior evidence that (+)-naloxone was able to block GA-induced pain 
(Lewis et al., 2010a), we hypothesized that GA and the structurally similar EtG would 
dock such that when (+)-naloxone was docked to MD-2, there would be a lower 
probability of GA or EtG docking.  The in silico docking analysis performed in 
Experiment 1A was repeated using a saved combined MD-2/(+)-naloxone pdb file to 
determine the change in docking due to the presence of already docked (+)-naloxone. The 
residues at which the lowest binding energy conformation of EtG docked to the MD-2 
were altered when (+)-naloxone was bound (Table 3.1).  In contrast, the residues at which 
the lowest binding energy conformation of GA docked were not altered by (+)-naloxone.  
Given prior evidence that (+)-naloxone was able to reverse GA-induced allodynia (Lewis 
et al., 2010a), the in silico data here does not predict, an any obvious manner, the 
physiological effect observed. This discrepancy may be explained by a second 
conformation, other than the lowest binding energy conformation, being responsible for 
the physiological effect, an allosteric effect on MD-2/TLR4 interactions, differences in 
human and rat MD-2/TLR4 structure, or inverse agonist actions of (+)-naloxone at MD-
2/TLR4, but such a distinction is beyond the capabilities of this in silico analysis. 
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24 X X   X 
29     X   
32 X       
44       G 
46 X X   X 
48 X X     
52 X X     
54 X X X   
55     X   
61 X     X 
63 X     X 
76 X     G 
94 X     G 
125     X   
126 X   X   
133         
135 X     X 
147 X     G 
149       X 
151 X X   X 
153 X X     
155     X   
157     X   
158     X   
 
Table 3.1.  In silico docking studies predict that GA and EtG will bind to the MD2 
portion of the TLR4-MD2 complex.  The residues on MD-2 at which GA and EtG 
interact with MD-2 are denoted with an X.  Residues that interacted with lipid A chains 
of lipopolysaccharide in the crystal structure determined by Park et al., (2009) are 
included for reference.  When the docking simulations were repeated with (+)-naloxone 
((+)-Nal) already bound to the MD2 molecule, the residues at which EtG interacted were 
altered, but the residues that GA interacted with did not change.  The residues that lost 
interaction with EtG when (+)-naloxone was already docked are denoted with a X.  
Residues that gained interaction when (+)-naloxone was already docked are denoted with 
a G. 
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Experiment 2A: In vitro TLR4-dependent SEAP expression in HEK-TLR4 cells is 
increased by GA, EtG and EtOH. 
 Experiment 1 provided initial evidence suggesting that EtG and GA may have 
effects on TLR4.  In order to determine if these effects were present in a cellular system, 
HEK-TLR4 cells were utilized.  As detailed in the methods, HEK-TLR4 cells have been 
transfected with TLR4 and a NFκB-dependent SEAP reporter gene.  Thus, an increase in 
TLR4 signaling will lead to an increase in NFκB transcription and subsequent increase in 
SEAP levels measured.  Previous studies have confirmed that HEK cells with the SEAP 
reporter gene but without TLR4 overexpression did not increase SEAP expression due to 
the classic TLR4 agonist LPS (Hutchinson et al., 2010b).  A dose-response function of 
TLR4 signaling changes for GA, EtG and EtOH was performed. 
 GA caused a significant increase in SEAP production in the HEK-TLR4 cells 
(F=19.16, p<0.05).  Post-hoc tests showed that GA increased SEAP expression relative to 
vehicle at the 10 µM and 100 µM concentrations, but was not significantly different from 
vehicle at lower concentrations (Figure 3.1A).  Similarly, EtG caused a significant 
increase in SEAP expression in HEK-TLR4 cells (F=19.44, p<0.05).  Post-hoc tests 
showed that EtG increased SEAP expression relative to vehicle at the 10 and 100 µM 
concentrations, but caused no significant changes at the lower concentrations (Figure 
3.1B).  Finally, EtOH also caused an increase in SEAP production in the HEK-TLR4 
cells (F=22.18, p<0.05).  However, Post-hoc tests showed that only the 100 µM 
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concentration of EtOH was significantly increased relative to vehicle, while the 0.01, 0.1, 
1 and 10 µM concentrations were not significantly different from the vehicle.  
 
Figure 3.1.  GA, EtG and EtOH all cause a significant increase HEK-TLR4 cell SEAP 
reporter expression.  GA caused a significant increase relative to vehicle at 10 and 100 
µM concentrations (F=19.16 p<0.05, A).  EtG caused a significant increase relative to the 
vehicle at 10 and 100 µM concentrations (F=19.44, p<0.05, B).  EtOH caused a 
significant increase relative to vehicle at the 100 µM concentration (F=22.18, p<0.05). 
 
Experiment 2B:  In vitro GA, EtG and EtOH induced increases in SEAP expression 
are blocked by the TLR4 antagonists LPS-RS and (+)-naloxone. 
Experiment 2A provides evidence that GA, EtG and EtOH were able to increase 
NFkB-dependent SEAP expression in HEK-TLR4 cells.  Here, the specificity of that 
response was tested by blocking the GA, EtG and EtOH-induced SEAP expression with 
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one of two TLR4 antagonists.  The first, LPS-RS, is structurally similar to LPS but fails 
to produce a TLR4-dependent proinflammatory response. It acts as a competitive 
antagonist of the LPS effects on TLR4 complex and has been shown to reduce the 
increase in SEAP expression caused by another glucuronidated metabolite, morphine-3-
glucuronide (Lewis et al., 2010a).  The second, (+)-naloxone, has also been shown to 
inhibit the LPS response in vitro (Hutchinson et al., 2008b; Hutchinson et al., 2010b) .  
Further, (+)-naloxone was able to block the increase in HEK-TLR4 SEAP expression 
caused by morphine-3-glucuronide (Hutchinson et al., 2010b) as well as the in vivo pain 
responses caused by both morphine-3-glucuronide and GA (Lewis et al., 2010a).  The in 
silico results of Experiment 1 further predict that (+)-naloxone would be able to block 
EtG-induced HEK-TLR4 cell SEAP expression.  
LPS-RS effectively blocked the increase in HEK-TLR4 SEAP expression caused 
by GA (F=7.51, p<0.05, Figure 3.2A), EtG (F=7.99, p<0.05, Figure 3.2C), and EtOH 
(F=30.0, p<0.05, Figure 3.2E).  Post-hoc tests showed that when 100 µM GA was 
incubated with either 0.1, 1 or 10 ng/ml of LPS-RS, SEAP expression was significantly 
decreased compared to 100 µM GA alone.  Similarly, when 100 µM EtG was incubated 
with either 0.1, 1 or 10 ng/ml of LPS-RS, SEAP expression was significantly decreased 
compared to100 µM EtG alone.  Finally, when 100 µM EtOH was incubated with either 
0.1, 1 or 10 ng/ml of LPS-RS, SEAP expression was significantly decreased compared to 
100 µM EtOH alone.  
(+)-Naloxone was also able to block the increase in HEK-TLR4 SEAP expression 
caused by 100 µM GA (F=5.36, p<0.05, Figure 3.2B), EtG (F= 4.92, p<0.05, Figure 
3.2D) or EtOH (F=8.36, p<0.05, Figure 3.2F).  Post-hoc tests showed that when 100 µM 
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GA was incubated with 1, 10 and 100 µM (+)-naloxone, SEAP expression was 
significantly decreased compared to 100 µM GA alone.  Similarly, when 100 µM EtG 
was incubated with 1 or 10 µM (+)-naloxone, SEAP expression was significantly 
decreased compared to 100 µM EtG alone.  Finally, when 100 µM EtOH was incubated 
with 1 and 10 µM (+)-naloxone, SEAP expression was significantly decreased compared 
to 100 µM EtOH alone.  
 
Figure 3.2. The TLR4 antagonist LPS-RS significantly attenuated the HEK-TLR4 cell 
SEAP increases seen with GA (F=7.51, p<0.05, A), EtG (F=7.99, p<0.05, C) and EtOH 
(F=30.0, p<0.05, E).  Similarly, the TLR4 antagonist (+)-naloxone significantly 
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attenuated the HEK-TLR4 cell SEAP increases seen with GA (F=5.36, p<0.05, B), EtG 
(F= 4.92, p<0.05, D) and EtOH (F=8.36, p<0.05, F). 
 
Experiment 3: Intrathecal GA and EtG cause tactile allodynia. 
The in silico and in vitro studies, above, strongly suggest that GA, EtG and EtOH 
are capable of activating TLR4.  Previous studies have shown that other glucuronide 
metabolites that can act as TLR4 agonists are able to produce pain in vivo (Lewis et al., 
2010a).   Additionally, previous studies have shown that GA was able to cause pain in 
vivo through TLR4-dependent mechanisms (Lewis et al., 2010a).  To confirm the 
nociceptive capability of GA and to determine if EtG and/or EtOH are able to cause 
allodynia, GA, EtG , EtOH or vehicle were injected intrathecally at equimolar doses and 
allodynia tested 1 and 3 h following injection. To test whether this TLR4 signaling 
activation was necessary for the development of GA and EtG-induced pain, LPS-RS was 
coadministered intrathecally with those drugs that caused a significant allodynia to 
develop.  Intrathecal LPS-RS has been shown to block neuropathic pain for a minimum 
of 3 h after an intrathecal injection (Hutchinson et al., 2008b).  Experiment 2B further 
indicated that LPS-RS was able to block the TLR4 signaling caused by both GA and EtG 
in vitro.   
In Experiment 3, no differences between right and left hind paws were detected. 
Thus, results are reported as the average of the response thresholds recorded for both 
paws.  There were also no baseline differences between any groups (F=0.458, p>0.05). 
Following intrathecal injection, GA caused significant allodynia (F=17.1, p<0.05, 
Figure 3.3A). Post-hoc test showed that  0.32 µg GA i.t. produced a robust decrease in 
tactile threshold relative to vehicle 1 and 3 h following injection, replicating the results of 
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Lewis et al. (2010a). The TLR4 antagonist LPS-RS was able to block the development of 
allodynia at the 3 h time point.   
EtG (0.38 µg, i.t.) also produced a robust decrease in tactile threshold (F=16.1, 
p<0.05, Figure 3.3B).  Post-hoc tests showed significant allodynia compared to vehicle at 
both 1 and 3 h following intrathecal injection.  This allodynia was blocked by LPS-RS at 
3 h post injection.  EtOH (0.07 µg, i.t.) failed to produce a significant change in tactile 
threshold relative to vehicle (F=0.204, p>0.05, Figure 3.3C).   
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Figure 3.3. GA (0.34 µg, i.t.)  caused a significant allodynia 3 hours post injection 
relative to vehicle injected rats, which was blocked by coadministered LPS-RS (40 µg, 
i.t.).  EtG (0.38 µg, i.t.) caused significant allodynia 1 and 3 hours post injection 
compared to vehicle injected rats at both time points which was blocked by 
coadministered LPS-RS (40 µg, i.t.).  Finally, EtOH (0.07 µg, i.t.) failed to cause 
allodynia within 3 hours of injection. All doses were equimolar. There were no baseline 
differences between any of the groups (F=0.133, p>0.05). 
 
DISCUSSION 
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 The present series of studies extend our prior observation of TLR4-dependent 
pain enhancement by the morphine metabolite, morphine-3-glucuronide (Lewis et al., 
2010a), by investigating whether such TLR4-dependent effects generalize to glucuronic 
acid (GA) itself or to other glucuronidated metabolites.  These studies present the first 
evidence that GA and the long-lived ethanol metabolite, Ethyl-β-D-glucuronide (EtG) 
each activate TLR4 signaling in vitro and produce a TLR4-activity dependent allodynia 
in vivo.  In addition, our in silico modeling based on the recently published crystal 
structure of TLR4 bound to its co-receptor MD-2 (Park et al., 2009) predicted that EtG 
would bind to MD-2 at a site in the same region as the recently documented TLR4 
antagonist, (+)-naloxone (Hutchinson et al., 2010b).  Further, the in silico docking of EtG 
to MD-2 was in a manner that was displaced by the prior docking of (+)-naloxone. These 
in silico results were substantiated in vitro using a HEK-TLR4 cell line that was stably 
transfected to produce a reporter protein in response to TLR4 activation. Studies of these 
cells revealed that GA, EtG and EtOH induced increases in HEK-TLR4 reporter protein 
expression were blocked by both (+)-naloxone and the classical TLR4 antagonist, LPS-
RS.  Lastly, while EtOH was able to increase HEK-TLR4 SEAP expression, it did not 
enhance pain following an intrathecal injection at a dose equimolar to EtG and GA. 
 The seemingly contradictory finding that EtOH increased HEK-TLR4 cell 
reporter protein expression in vitro, but failed to cause allodynia when administered 
intrathecally, may arise from differences in in vitro versus in vivo conditions.  First, 
EtOH was injected intrathecally at a dose equimolar to allodynia-inducing doses of GA 
and EtG.  Thus EtOH was delivered at a dose of 0.074 µg. It is possible that with such a 
small dose, there was not sufficient diffusion into spinal tissues from cerebrospinal fluid 
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(CSF) and/or that EtOH so rapidly diffuses out of the central nervous system that there 
was insufficient exposure of lumbar dorsal horn to create a detectable change in pain 
threshold. While a higher dose may potentially cause significant allodynia, based on the 
HEK-TLR4 results, a higher intrathecal dose of EtOH was not tested here both because 
the strategy was to compare equimolar doses and because allodynia by higher doses had 
the potential to result from confounding toxicity of alcohol on central nervous system 
tissues.  A second possible explanation for the apparent contradictory findings for EtOH 
is that EtOH also enhances the inhibitory function of GABAA receptors (Lobo and Harris, 
2008) which could counteract a TLR4-induced increase in neuronal excitability. 
 One important question is whether the TLR4-dependent effects of EtG might 
impact the known symptoms of EtOH use.  In a model based on 75 g of EtOH ingestion, 
serum EtOH peaks 1-2 hours following the end of drinking, while serum EtG peaks 
approximately 6 hours after the end of drinking (Droenner et al., 2002).  Little data are 
available on CSF levels of EtG, although EtG was detected at 0.31 µg/ml in a human who 
died due to acute alcohol intoxication (Wurst et al., 1999).  Notably, several pain-related 
effects of EtOH in humans, such as alcohol withdrawal hyperalgesia (Jochum et al., 
2010) and headache after both chronic (Martinotti et al., 2010) and acute (e.g. hangover, 
(Howland et al., 2008) EtOH ingestion, are associated not with high levels of EtOH, but 
with declining levels of EtOH.  Additionally, withdrawal from chronic alcohol exposure 
in rats has been linked to an increase in microglial activation markers and allodynia 
(Narita et al., 2007).  EtG concentrations peak while EtOH is declining, meaning that EtG 
levels are highest when these negative side effects are observed.  Many alternative 
hypotheses for these pain-producing side effects have been postulated, however, the exact 
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cause is unknown.  While further study is needed to determine if EtG contributes to the 
negative side effects of EtOH, the potential exists and warrants additional study. 
While EtOH is largely an exogenous drug, with only very small amounts made 
endogenously, GA is principally found endogenously throughout the body.  However, it 
is usually either conjugated to form uridine 5’-diphosphoglucuronic acid, the substrate for 
the glucuronyltransferases that form glucuronidated metabolites, or polymerized with N-
acetyl-D-glucosamine to form the extracellular matrix component hyaluronan.  
Hyaluronan polymers have been shown to have anti-inflammatory properties (Huang et 
al., 2011). However, smaller, low molecular weight polymers have been shown to 
activate TLR4 (Li et al., 2010; Leu et al., 2011).  This finding is of particular significance 
in several pathological conditions, including pulmonary arterial hypertension (Ormiston 
et al., 2010), atherosclerosis (Cuff et al., 2001), and rheumatoid arthritis (Naor and 
Nedvetzki, 2003), where low molecular weight hyaluronan and its adhesion receptor 
CD44 have been associated with increased inflammation and disease progression. The 
studies here suggest that the glucuronide component of hyaluronan may contribute to the 
inflammatory effects of hyaluronan, and also suggest that TLR4 be considered as an 
additional candidate receptor for these inflammatory effects.   
EtG and GA are structurally very similar.  A logical question is whether the 
modification of GA by adding an ethyl group alters the in silico, in vitro and in vivo 
effects observed.  In silico, EtG and GA appear to interact with different residues on MD-
2, suggesting that there may be differences.  However, in vitro and in vivo the results for 
the two drugs were not significantly different and in fact quite similar. It appears the 
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addition of the ethyl group to glucuronic acid did not dramatically alter the effects 
observed, although it may have altered the most likely predicted docking site in silico. 
These studies present evidence that the glucuronide molecules GA and EtG may 
produce pain through TLR4-dependent mechanisms. EtOH also had potential TLR4 
activity, but did not cause pain this particualar in vivo model.  The finding that GA and 
EtG can cause TLR4-dependent pain in and of themselves has potentially wide-ranging 
implications for conditions such as hangover, chronic alcohol withdrawal headache and 
several disorders, such as rheumatoid arthritis and atherosclerosis, linked to low 
molecular weight hyaluronan.  Additionally, the TLR4-dependent pain effect morphine-
3-glucuronide has now generalized to additional classes of molecules, including 
glucuronic acid alone and ethyl glucuronide.  This finding suggests that other classes of 
molecules that are glucuronidated, such as steroid hormones and non-steroidal anti-
inflammatories, could also have TLR4-dependent pain producing effects. 
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ABSTRACT 
We have recently shown that several classes of glucuronide metabolites, including the 
morphine metabolite morphine-3-glucuronide and the ethanol metabolite ethyl 
glucuronide, cause toll like receptor 4 (TLR4)-dependent signalling in vitro and enhanced 
pain in vivo.  Another major class of glucuronidated compounds is the steroid hormones, 
including estrogens and corticosterone. Here we demonstrate that an in silico docking 
study predicts that corticosterone, corticosterone-21-glucuronide, estradiol, estradiol-3-
glucuronide and estradiol-17-glucuronide would all interact with the MD-2 component of 
the TLR4 receptor complex. In addition to each docking with MD-2, the docking of each 
was altered by pre-docking with (+)-naloxone, a TLR4 signaling inhibitor.  As, 
agonist/antagonist activity cannot be determined from these in silico interactions, an in 
vitro study was undertaken to clarify which of these compounds can act in an agonist 
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fashion.  Studies using a cell line transfected with TLR4, necessary co-signaling 
molecules, and a reporter gene revealed that only estradiol-3-glucuronide and estradiol-
17-glucuronide increased reporter gene product, indicative of TLR4 agonism.  Finally, in 
in vivo studies, each of the 5 drugs was injected intrathecally at equimolar doses.  In 
keeping with the in vitro results, only estradiol-3-glucuronide and estradiol-17-
glucuronide caused enhanced pain. For both compounds, pain enhancement was blocked 
by the TLR4 antagonist lipopolysaccharide from Rhodobacter sphaeroides, evidence for 
the involvement in TLR4 in the resultant pain enhancement.  These findings have 
implications for several chronic pain conditions, including migraine and 
tempromandibular joint disorder, in which pain episodes are more likely in cycling 
females when estradiol is decreasing and estradiol metabolites are at their highest. 
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 Recent evidence suggests that certain glucuronide metabolites have 
neuroinflammatory actions.  Specifically, morphine-3-glucuronide, ethyl-β-D-
glucuronide and glucuronic acid have been shown to activate the innate immune toll-like 
receptor 4 (TLR4) and cause TLR4-dependent enhanced pain when administered 
intrathecally (Lewis et al., 2010a; Lewis et al., 2011a). Another major class of 
glucuronidated molecules is the steroid hormones.  Androgens (Belanger et al., 1994), 
estrogens (Guillemette et al., 2004), and corticosteroids (Ikegawa et al., 2009) are all 
glucuronidated as part of metabolism.  However, the potential for TLR4 activation and/or 
enhanced nociception by these glucuronidated metabolites has not been studied. 
 Several of the steroid hormones also have associations with enhanced pain, 
including corticosterone (Cort) and estradiol (E2).  Acute stress and acute stress-
associated corticosterone release in rats has been shown to inhibit nociception, while 
chronic stress has been linked to hyperalgesia, although analgesic effects have also been 
reported (Imbe et al., 2006).  Clinically, chronic stress has also been associated with 
chronic pain conditions such as fibromyalgia, chronic headache, inflammatory bowel 
disease and tempromandibular joint pain (McEwen and Kalia, 2010).  Cort, intriguingly, 
has both anti-inflammatory and pro-inflammatory effects on inflammation caused by the 
classic TLR4 ligand lipopolysaccharide (LPS).  Cort inhibits proinflammation by LPS 
when LPS precedes Cort, whereas Cort potentiates proinflammation by LPS when LPS is 
given 2 or 24 hours following Cort (Frank et al., 2010).  One potential explanation for 
this finding is that the anti-inflammatory effect of Cort was modulated by a 
proinflammatory effect of its glucuronidated metabolite.  Cort is metabolized by 
extensive degradation or conjugation with a glucuronide group to form corticosterone-21-
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glucuronide (CortG).  CortG has been found in mouse brain homogenates, indicating that 
it has the potential to directly affect the central nervous system (Kallonen et al., 2009). 
 Another steroid hormone that has been linked to increased pain is E2.  Estrogens, 
including E2, are the primary female sex hormones and, clinically, women are almost 
twice as likely to have chronic pain conditions (Craft, 2007).  Additionally, the drop from 
peak E2 levels during pre-menses in women is associated with an increased risk of 
migraine and increased tempromandibular joint pain (Craft, 2007).  E2 may also affect the 
LPS response. Chronic E2 administration in ovariectomized females and male rats 
increased the LPS –stimulated inflammatory response in hippocampal microglia ex vivo 
and increased proinflammatory cytokine transcription in vivo (Loram et al., 2011).  E2  is 
metabolized into estradiol-3-glucuronide (E2-3-G) and estradiol-17-glucuronide (E2-17-
G), and both of these metabolites have also been found in brain tissue homogenates, 
indicating that they have access to the central nervous system (Kallonen et al., 2009).  
Neither metabolite is believed to have activity at the estrogen receptors. 
 The first step to determine if glucuronidated Cort and E2 metabolites could 
contribute to the pain-enhancing effects of the parent hormones is to determine if the 
metabolites have the ability to potentiate pain. Given the TLR4-dependent allodynia 
caused by other glucuronidated metabolites, we hypothesize that CortG, E2-3-G and E2-
17-G will cause an increase in TLR4 signaling as well as TLR4-dependent enhanced 
pain.   
MATERIALS AND METHODS 
Drugs  Cort, E2, E2-3-G, and E2-17-G were purchased from Sigma (St. Louis, MO).  
CortG was synthesized by the authors (MMF, TS) from D-(+)-glucurono-6,3-lactone.  
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The lactone was converted to the protected trichloroacetimidate by the procedure of 
Nakajima et al. (2005), coupled with corticosterone, then deprotected according to the 
procedure of Ciuffredaa et al. (2009). The identity of the product was confirmed by 
comparison of 1H and 13C NMR data with that reported by Ciuffredaa et al. (2009).  
Lipoplysaccharide from Rhodobacter sphaeroides (LPS-RS) was purchased from 
Invivogen (Thousand Oaks, CA) and (+)-naloxone was obtained from the National 
Institute on Drug Abuse.  CortG, E2-3-G, LPS-RS and (+)-naloxone were dissolved in 
endotoxin-free sterile water (Hospira, Lake Forest, IL) for in vitro studies (Experiment 2) 
and endotoxin-free, sterile 0.9% saline (Hospira, Lake Forest, IL) for in vivo studies 
(Experiment 3).  E2-17-G was dissolved in 10% DMSO (Sigma, St. Louis, MO) and 
sterile water for in vitro studies (Experiment 2) and 1% DMSO and sterile saline for in 
vivo studies (Experiment 3).  Cort and E2 were dissolved in 100% DMSO for both in 
vitro and in vivo studies.  Cort, CortG, E2, E2-3-G, and E2-17-G, (+)-naloxone, saline and 
water were all confirmed to be endotoxin-free by the limulus amebocyte lysate assay 
(Lonza, Walkersville, MD).  Where appropriate, doses are reported as a free base 
concentration. 
 
In silico docking simulations 
In silico docking simulation methods were identical to those previously described 
in detail (Hutchinson et al., 2010b). These were employed to examine the docking of 
Cort, CortG, E2, E2-3-G, and E2-17-G to the TLR4/MD-2 complex.  The in silico docking 
analyses were conducted in Experiment 1 using the recently published high-resolution 
crystalline structure of the dimer of human TLR4 and MD-2 (Park et al., 2009) and the in 
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silico docking software suite AutoDock 4.  Briefly, the complexed human TLR4 and 
MD-2 pdb file was obtained from RCSB Protein Data Bank database (PDBID: 3fxi). 
Modified pdb files were inputted into AutoDock 4.0 (http://autodock.scripps.edu), 
hydrogens added, and resaved in pdbqt format. Structures were gathered using PubChem 
isomeric SMILES then converted to .pdb using a structure file generator 
(http://cactus.nci.nih.gov/services/translate/). All dockings were executed with Lamarkian 
genetic algorithms.  
 
In vitro assay for TLR4 signaling 
A human embryonic kidney-293 (HEK 293) cell line was used in Experiment 2. 
This cell line was stably transfected by Invivogen (San Deigo, CA) to over-express 
human TLR4 and co-receptor molecules (MD-2, CD14) (293-htlr4a-md2cd14; referred to 
here as HEK-TLR4). In addition, these cells stably express an optimized alkaline 
phosphatase reporter gene under the control of a promoter inducible by transcription 
factors, such as NFκB and AP-1, activated as part of the TLR4 signaling cascade. 
Secreted alkaline phosphatase (SEAP) protein is produced as a consequence of TLR4 
activation.  
HEK-TLR4 cells were grown at 37oC (5% CO2; VWR incubator model 2300) in 10 
cm dishes (Greiner Bio-One, CellStar 632171; Monroe, NC, USA) in normal supplement 
selection media (DMEM  media [Invitrogen, Carlsbad, CA, USA] supplemented with 
10% fetal bovine serum [Hyclone; Logan, UT, USA], HEK-TLR4 selection [Invivogen]; 
Penicillin 10,000 U/ml [Invitrogen]; streptomycin 10 mg/ml [Invitrogen], Normocine 
[Invivogen], and 200 nM L-Glutamine [Invitrogen]).  The cells were then plated for 48 h 
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in 96 well plates (Microtest 96 well plate, flat bottom, Becton Dickinson; 5 x 103 
cells/well) with the same media. After 48 h, supernatants were removed and replaced 
with fresh media.  Drugs tested were added in concentrations indicated and incubated for 
24 h.  Supernatants (15 µl) were then collected from each well for immediate assay. 
SEAP levels in the supernatants were assayed using the Phospha-Light System 
(Applied Biosystems) according to the manufacturer’s instructions.  This 
chemiluminescent assay incorporates Tropix CSPD chemiluminescent substrate.  The 15 
µl test samples were diluted in 45 µl of 1x dilution buffer, transferred to 96-well plates 
(Thermo, Walthma, MA, USA), and heated at 65oC in a water bath (Model 210, Fisher 
Scientific, Pittsburgh, PA, USA) for 30 min, then cooled on ice to room temperature.  
Assay buffer (50 µl/well) was added and, 5 min later, reaction buffer (50 µl/well) is 
added and allowed to incubate for 20 min at room temperature.  The light output is then 
measured in a microplate luminometer (Dynex Technologies, #IL213.1191, Chantilly, 
VA, USA). 
 
In vivo behavioral assessments 
 Animals. Adult, male, pathogen-free Sprague-Dawley rats (Harlan Labs, Madison, 
WI) were used for all in vivo experiments.  Rats (325-375 g at time of experiments) were 
housed in temperature (23±3 oC) and light (12 h:12 h light:dark) controlled rooms with 
water and food given ad libitum.  All habituation and behavioral testing procedures were 
performed during the light phase of the daily cycle.  All procedures were approved by the 
University of Colorado-Boulder Institutional Animal Care and Use Committee.  Each 
experimental group contains 6-8 rats. 
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Intrathecal catheter implantation and injections.  Acute intrathecal injections 
were used to administer drugs in Experiment 3.  Catheter placements via the L5/L6 
intervertebral approach and drug microinjections were performed based on Milligan et al. 
(1999). Rats were briefly anaesthetized under isoflurane anesthesia. An 18-gauge needle 
was placed between L5 and L6 into the intrathecal space and served as a guide.  
Polyethylene-10 tubing was threaded rostrally through the guide so to terminate over the 
lumbosacral enlargement. The catheters were pre-loaded with drugs at the intrathecal end 
and the remainder filled with sterile saline. Upon insertion, the drug was injected with an 
8.5 µl flush to ensure complete drug delivery, and the needle and catheter then removed.  
The rats were anaesthetized for, on average, 5 minutes and had no skin incision or 
implantations upon awakening. 
All drugs administered in vivo in Experiment 3 were given intrathecally over 
lumbosacral spinal cord.  All doses were equimolar with the doses of glucuronide 
metabolites (morphine-3-glucuronide, ethyl glucuronide and glucuronic acid) that were 
sufficient to cause allodynia in prior studies (Lewis et al., 2010a; Lewis et al., 2011a).  
Cort was given at a dose of 0.56 µg and CortG was given at a dose of 0.85 µg.   E2 was 
given at a dose of 0.44 µg, E2-3-G and E2-17-G were both given at doses of 0.76 µg.  
LPS-RS was given at an intrathecal dose of 40 µg, consistent with previous literature 
showing this dose was capable of reversing neuropathic pain (Hutchinson et al., 2008b). 
 
von Frey test for tactile allodynia. All testing was conducted by an experimenter 
blind to group assignment. Rats received at least four 1 h habituations to the appropriate 
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testing apparatus and environment prior to baseline testing, as in our previous studies 
(Lewis et al., 2010a). 
The response threshold to light touch on both plantar hind paws was measured 
using calibrated microfilaments (von Frey hairs; Stoelting, Wood Dale, IL, USA), as 
described in Milligan et al. (2001).  Briefly, a logarithmic range of hairs from 0.406-
15.136 g force were used, allowing both analgesia and allodynia to be measured, 
following the standard up-down procedures previously described (Chaplan et al., 1994). 
Responses were fitted to a Gaussian integral psychometric function using a maximum-
likelihood fitting method as described in Milligan et al. (2001).  
 
Statistics 
 GraphPad Prism (version 5 for Windows, San Diego, CA) software was used for 
all statistical analyses. One-way ANOVAs with appropriate Bonferroni post hocs were 
used to compare experimental groups on in vitro experiments and to confirm that there 
were no baseline differences on behavioral measures. Two-way repeated-measures 
ANOVAs with Bonferroni post-hoc tests when appropriate were used to determine 
statistical significance between behavioral measures.  For all analyses, p<0.05 was 
considered significant. 
 
Experimental Procedures 
 
Experiment 1A: Does in silico docking predict that Cort, CortG, E2, E2-3-G, and/or 
E2-17-G will bind to TLR4/MD2?    
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Initially, the in silico docking of Cort, CortG, E2, E2-3-G, and E2-17-G to the 
entire TLR4 MD-2 dimer complex was conducted (AutoGrid center set 3.438, -7.805, 
2.034; 126 grid points expanding in all directions; genetic algorithm running number of 
100, Max Evals 5 × 106 and 1.0 Å spacing). Additionally, all the ligands were docked to 
MD-2 alone with greater resolution (AutoGrid center set 27.991, 0.851, 19.625; 126 grid 
points expanding in all directions; genetic algorithm running number of 100, Max Evals 5 
× 106 and 0.375 Å spacing). The lowest energy and highest interaction docking 
conformation was visualized and the residues on MD-2 that interacted with that 
conformation determined for each of the experimental drugs. 
 
Experiment 1B: For drugs predicted to dock to the TLR4/MD-2 complex in 
Experiment 1A, would previously docked (+)-naloxone reduce the likelihood of their 
in silico docking? 
The (+)-naloxone conformation from a previous study (Lewis et al., 2010a) was 
saved as a combined MD-2/(+)-naloxone pdb file and the Cort, CortG, E2, E2-3-G, and/or 
E2-17-G in silico docking was repeated on the combined MD-2/(+)-naloxone complex to 
determine the change in docking due to the presence of already docked (+)-naloxone.  
 
Experiment 2A: Does in vitro Cort, CortG, E2, E2-3-G, and/or E2-17-G cause an 
increase in TLR4-dependent SEAP expression in HEK-TLR4 cells? 
 The experimental drugs, Cort, CortG, E2, E2-3-G, and/or E2-17-G were each 
applied to HEK-TLR4 cells at concentrations of 0, 1, 10 and 100 µM as described above.  
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Cells were incubated for 24 h, then supernatants removed and assessed for SEAP activity, 
indicative of TLR4-induced NFκB activity. 
 
Experiment 2B: Is the in vitro increase in TLR4-dependent SEAP expression seen in 
Experiment 2A blocked by the TLR4 inhibitors LPS-RS and/or (+)-naloxone? 
 For drugs which increase HEK-TLR4 SEAP production in Experiment 2A, the 
most effective dose (100 µM for each) was applied to HEK-TLR4 cells as described 
above.  Additionally, one of two TLR4 antagonists was coadministered.  One, 
lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS, Invivogen, San Diego, CA), 
lacks functional TLR4 activity and acts as a competitive TLR4 antagonist.  LPS-RS was 
applied to the HEK-TLR4 cells at the same time as the E2, E2-3-G, or E2-17-G at 
concentrations of 0, 0.1, 1 or 10 ng/ml. The other, (+)-naloxone, is the opioid-inactive 
isomer of naloxone and has been shown to antagonize LPS-induced increases in HEK-
TLR4 signaling (Hutchinson et al., 2010b). (+)-Naloxone was applied to the HEK-TLR4 
cells at the same time as the E2, E2-3-G, and/or E2-17-G at concentrations of 0, 1, 10 or 
100 µM.  For all assays, cells were incubated for 24 h, then supernatants removed and 
assessed for SEAP activity, indicative of TLR4 activity.  
 
Experiment 3: Does intrathecal Cort, CortG, E2, E2-3-G, and/or E2-17-G cause 
tactile allodynia? Is that allodynia TLR4 dependent? 
Rats received either Cort (0.56 µg), CortG (0.85 µg), E2 (0.44 µg), E2-3-G (0.76 
µg), and/or E2-17-G (0.76 µg) or equivolume (1 µl) vehicle via an acute intrathecal 
injection, as described above.  Both injections had a saline flush for a total injection 
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volume of 9.5 µl. Rats were tested for tactile allodynia 1 d prior to injection (baseline; 
BL) and again 1 and 3 h post-injection.   
 The drugs that produced significant allodynia (in this case, E2-3-G and E2-17-G) 
were coadministered with the TLR4 antagonist LPS-RS.  Rats received 0.76 µg of either 
E2-3-G, E2-17-G or equivolume (1 µl) saline with 40 µg LPS-RS via an acute intrathecal 
injection. 
 
RESULTS 
Experiment 1A: In silico modeling predicts that Cort, CortG, E2, E2-3-G, and E2-17-
G will bind to MD-2. 
An in silico docking study was done to determine if Cort, CortG, E2, E2-3-G, 
and/or E2-17-G would be predicted to dock to the TLR4/MD-2 complex.  This in silico 
technique has been successfully used previously to model the docking of morphine-3-
glucuronide, other opioid drugs, tricyclic antidepressants, ethanol glucuronide, glucuronic 
acid and other compounds (Hutchinson et al., 2010a; Hutchinson et al., 2010b; Lewis et 
al., 2010a; Lewis et al., 2011a). 
The in silico docking of Cort, CortG, E2, E2-3-G, and E2-17-G to the entire TLR4 
MD-2 dimer complex was initially conducted (AutoGrid center set 3.438, -7.805, 2.034; 
126 grid points expanding in all directions; genetic algorithm running number of 100, 
Max Evals 5 × 106 and 1.0 Å spacing). These data demonstrated that the ligands each 
docked with human MD-2 independent of human TLR4 interactions. Therefore, the 
ligands were then docked to MD-2 alone with greater resolution (AutoGrid center set 
27.991, 0.851, 19.625; 126 grid points expanding in all directions; genetic algorithm 
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running number of 100, Max Evals 5 × 106 and 0.375 Å spacing). The lowest energy and 
highest interaction docking conformation was visualized for each drug and the residues 
on MD-2 that each drug interacted with are listed in Table 4.1.  Additionally, Cort, 
CortG, E2, E2-3-G, and E2-17-G all had a preferred conformation with a negative 
predicted docking energy, suggesting that they would be likely to dock to the MD2 
molecule. 
 
Experiment 1B:  (+)-naloxone alters the predicted MD-2 docking conformations of 
Cort, CortG, E2, E2-3-G, and E2-17-G in silico. 
Given prior evidence that (+)-naloxone altered the predicted in silico docking of 
other glucuronide molecules and successfully blocked HEK-TLR4 signaling of these 
same molecules in vitro (Hutchinson et al., 2010b; Lewis et al., 2010a; Lewis et al., 
2011a)  we hypothesized that CortG, E2-3-G, and E2-17-G would dock on MD-2 such 
that when (+)-naloxone was docked to MD2, the drugs of interest would be less likely to 
dock.  Similarly, in Experiment 1A, Cort and E2 were also predicted to dock to MD-2 at 
similar residues to the glucuronide metabolites, and we hypothesize that this docking 
would also be altered by the presence of (+)-naloxone. 
The in silico docking analysis performed in Experiment 1A was repeated utilizing 
a saved combined MD-2/(+)-naloxone pdb file to determine the change in docking due to 
the presence of (+)-naloxone docked to the MD2 molecule.  Additionally, for all the 
molecules, the residues at which the lowest binding energy conformation in Experiment 
1A interacted were altered by the presence of (+)-naloxone (Table 4.1).  However, the 
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functional effects of any of these compounds docking to MD2 are beyond the capability 
of this in silico study. 
residue 
lipid 
A 
(+)-
Nal Cort CortG E2 
E2- 
3-G 
E2- 
17-G 
24 X X 
 X    
32 X X X X   X  
44     X   G   X 
46 X X X X X X X 
48 X X 
 X   X 
52 X X X X   X 
54 X X           
61 X   X X X X X 
63 X   X X X X X 
71 X       X X   
74 X       X X X 
76 X   G X X X X 
78 X   G G   G  
92     G        
94 X   G G G   X 
102         G     
104 X   G   X X X 
117 X   G G   G X 
119 X   
  
    G 
121 X   
 
      G 
133     G X   G   
135 X   X X       
147 X   X G X X X 
149         G   X 
151 X X X X X X X 
153 X X 
 
X       
Table 4.1: In silico docking studies predict that Cort, CortG, E2, E2-3-G, and E2-17-
G will dock to the MD2 portion of the TLR4-MD2 complex.  The residues on MD-2 at 
which these compounds interact with MD-2 are denoted with an X.  Residues that 
interacted with lipid A chains in the crystal structure determined by Park et al., (2009) are 
included for reference.  When the docking simulations were repeated with (+)-naloxone 
((+)-Nal) already bound to the MD2 molecule, the residues at which each drug interacted 
were altered.  The residues that lost interaction with EtG when (+)-naloxone was already 
docked are denoted with a X.  Residues that gained interaction when (+)-naloxone was 
already docked are denoted with a G. 
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Experiment 2A: In vitro TLR4-dependent SEAP expression in HEK-TLR4 cells is 
increased by E2-3-G and E2-17-G and decreased by E2 and Cort. 
 Experiment 1 provided initial evidence suggesting that Cort, CortG, E2, E2-3-G 
and E2-17-G may have effects on TLR4.  In order to determine if these effects were 
present in a cellular system, HEK-TLR4 cells were utilized.  As detailed in the methods, 
HEK-TLR4 cells have been transfected by Invivogen for overexpression of TLR4 and its 
co-receptors and a NFκB-dependent SEAP reporter gene.  Thus, an increase in TLR4 
signaling will lead to an increase in NFκB transcription and subsequent increase in SEAP 
levels measured.  Previous studies have confirmed that HEK cells with the SEAP reporter 
gene but without TLR4 overexpression did not increase SEAP expression to the classic 
TLR4 agonist LPS (Hutchinson et al., 2010b).  The dose-response functions for Cort, 
CortG, E2, E2, E2-3-G and E2-17-G on HEK-TLR4 SEAP expression were calculated. 
 Cort caused a significant decrease in SEAP production in the HEK-TLR4 cells 
relative to its 1% DMSO vehicle (F=9.05, p<0.05).  Post-hoc tests showed that Cort 
decreased SEAP expression relative to vehicle at 0.1, 1 and 10 µM concentrations, but 
was not significantly different from vehicle at the 100 or 0.01 µM concentrations (Figure 
4.1A).  CortG, however, caused no significant alterations from its saline vehicle (F=1.72, 
p>0.05, Figure 4.1B). 
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Figure 4.1.  Corticosterone caused a significant decrease in HEK-TLR4 cell SEAP 
reporter expression at 0.1, 1 and 10 µM concentrations (F=9.05, p<0.05).  CortG did not 
cause any changes in HEK-TLR4 SEAP expression compared to vehicle (F=1.72, 
p>0.05, B). 
 
E2 caused a significant decrease in SEAP expression in the HEK-TLR4 cells 
(F=9.60, p<0.05).  Post-hoc tests showed that E2 decreased SEAP expression relative to 
vehicle at the 0.01, 0.1, 1 and 10 µM concentrations, but caused no change at the 100 µM 
concentration (Figure 4.2A).  E2-3-G, on the other hand, caused an increase in SEAP 
production in the HEK-TLR4 cells (F=19.2, p<0.05).  Post-hoc tests confirmed that all 
five concentrations of E2-3-G tested (0.01. 0.1, 1, 10 and 100 µM) were significantly 
increased relative to vehicle (Figure 4.2B).  Finally, E2-17-G also caused a significant 
increase in HEK-TLR4 SEAP expression (F=72.81, p<0.05), but post-hoc tests showed 
this difference only at the 100 µM concentration (Figure 4.2C). 
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Figure 4.2.  E2 caused a significant decrease in HEK-TLR4 cell SEAP reporter gene 
expression relative to 1% DMSO vehicle at 0.01, 0.1, 1 and 10 µM concentrations 
(F=9.60, p<0.05, A).  E2-3-G caused a significant increase in HEK-TLR4 cell NFκB-
dependent SEAP expression relative to water vehicle at 0.01, 0.1, 1, 10 and 100 µM 
concentrations (F=19.2, p<0.05, B).  E2-17-G also caused a significant increase in HEK-
TLR4 cell SEAP expression relative to 0.1% DMSO vehicle at the 100 µM concentration 
(F=72.81, p<0.05). 
 
Experiment 2B:  In vitro E2-3-G and E2-17-G induced increases in SEAP expression 
are blocked by the TLR4 inhibitors LPS-RS and (+)-naloxone.  
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 Both E2-3-G and E2-17-G caused a robust increase in SEAP expression in the 
HEK-TLR4 cells in Experiment 2A.  To test whether this was a TLR4-specific effect, 
two TLR4 inhibitors, LPS-RS and (+)-naloxone, were coincubated with E2-3-G and E2-
17-G to determine if the TLR4 inhibitors blocked the SEAP increases seen with the drugs 
alone.  LPS-RS acts as a competitive antagonist of the LPS effects on TLR4 complex as 
is structurally similar to LPS but fails to produce a TLR4-dependent proinflammatory 
response.  The second inhibitor, (+)-naloxone, has also been shown to antagonize the LPS 
response in vitro (Hutchinson et al., 2008b) and has been documented by a broad 
receptor, enzyme, and second messenger screen to have no identified off-target effects 
(Northcutt et al., 2010).   
 LPS-RS effectively blocked the increase in HEK-TLR4 cell SEAP expression 
caused by E2-3-G (F=5.22, p<0.05, Figure 4.3A) and E2-17-G (F=7.81, p<0.05, Figure 
4.3C).  Posthoc tests showed that when 100 µM E2-3-G was incubated with 0.1, 1 or 10 
ng/ml LPS-RS, SEAP expression was significantly decreased compared to 100 µM E2-3-
G alone.  Similarly, when100 µM E2-17-G was incubated with 0.1, 1 or 10 ng/ml LPS-
RS, SEAP expression was also significantly decreased compared to 100 µM E2-17-G 
alone. 
 (+)-Naloxone also blocked the increase in HEK-TLR4 cell SEAP expression 
caused by E2-3-G (F=6.89, p<0.05, Figure 4.3B) and E2-17-G (F=9.17, p<0.05, Figure 
4.3D).  Posthoc tests showed that when 100 µM E2-3-G was incubated with 1 or 10 µM 
(+)-naloxone, SEAP expression was significantly decreased compared to 100 µM E2-3-G 
alone.  Similarly, when 100 µM E2-17-G was incubated with 10 or 1 µM (+)-naloxone, 
SEAP expression was also significantly decreased compared to 100 µM E2-17-G alone. 
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Figure 4.3. The TLR4 antagonist LPS-RS significantly attenuated the HEK-TLR4 cell 
SEAP increases caused by 100 µM E2-3-G (F=5.22, p<0.05, A) or 100 µM E2-17-G 
(F=7.81, p<0.05, C) at all three concentrations tested (0.1, 1 and 10 ng/ml).  Similarly, 
the TLR4 inhibitor (+)-naloxone significantly attenuated the HEK-TLR4 cell SEAP 
increases caused by 100 µM E2-3-G (F=6.89, p<0.05, B), or 100 µM E2-17-G (F= 9.17, 
p<0.05, D) at the 1 and 10 µM concentrations. 
 
Experiment 3: E2-3-G and E2-17-G cause tactile allodynia that is blocked by the 
TLR4 antagonist LPS-RS. 
 The in silico and in vitro studies above strongly suggest that E2-3-G and E2-17-G, 
but not Cort, CortG or E2, are capable of activating TLR4. Previous studies have shown 
that other glucuronide metabolites that can act as TLR4 agonists are able to produce pain 
in vivo (Lewis et al., 2010a).  To determine if the drugs investigated here caused increase 
tactile sensitivity, equimolar Cort, CortG, E2, E2-3-G and E2-17-G were injected via an 
acute intrathecal injection over the lumbar enlargement and allodynia measured 1 and 3 
hours following injection.  Experiments 1 and 2 predict that E2-3-G and E2-17-G will 
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enhance TLR4 signaling.  Previous studies suggest that TLR4 activity can cause 
enhanced pain in vivo (Hutchinson et al., 2008b; Lewis et al., 2010a).  To determine if 
TLR4 activity was necessary for drugs which caused allodynia in this study, a TLR4 
antagonist, LPS-RS was coadministered and allodynia again assessed 1 and 3 hours post-
injection.  LPS-RS successfully blocked E2-3-G and E2-17-G induced SEAP expression 
in HEK-TLR4 cell and has been used to block pain following glucuronic acid or ethyl 
glucuronide administration in vivo (Lewis et al., 2010a). 
No differences between right and left hind paws were detected. Thus, results are 
reported as the average of the response thresholds recorded for both paws. There were 
also no baseline differences between any of the behavior groups (F=1.86, p>0.05). 
  Intrathecal Cort (0.56 µg) and its equivolume (1 µl) 1% DMSO vehicle each 
caused an increase in tactile sensitivity relative to baseline, and did not differ from each 
other (F=0.33, p>0.05, Figure 4.4A).  Intrathecal CortG (0.85 µg), however, did not cause 
allodynia to develop relative to its saline vehicle (F=0.17, p>0.05, Figure 4.4B).   
Similar to Cort, intrathecal E2 (0.44 µg) and its equivolume (1 µl) 1% DMSO 
vehicle both caused a decrease in sensitivity relative to baseline but did not differ from 
each other (F=2.17, p>0.05, Figure 4.4C).  Intrathecal E2-3-G (0.76 µg), however, caused 
a robust tactile allodynia 1 and 3 hours post injection which was blocked by 40 µg LPS-
RS (F=42.8, p<0.05, Figure 4.4D).  E2-17-G (0.76 µg) also caused significant tactile 
allodynia to develop 3 hours post injection that was blocked by 40 µg LPS-RS (F=9.303, 
p<0.05, Figure 4.4E).   
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Figure 4.4.  Intrathecal injection of Cort (0.56 µg, F=0.33, p>0.05, A), CortG (0.85 µg, 
F=0.17, p>0.05, B) or E2 (0.44 µg, F=1.07, p>0.05, C) failed to cause significant 
allodynia relative to vehicle controls.  Intrathecal injection of E2-3-G (0.76 µg, F=42.8, 
p<0.05, D) and E2-17-G (0.76 µg, F=4.63, p<0.05, E) caused significant allodynia to 
develop.  Coadministration of LPS-RS (40 µg, intrathecal) blocked the development of 
the allodynia caused by E2-3-G (F=24.36, p<0.05, D) and E2-17-G (F=6.02, p<0.05, E). 
 
DISCUSSION 
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 These studies sought to determine if the steroid hormone glucuronide metabolites 
corticosterone-21-glucuronide (CortG), estradiol-3-glucuronide (E2-3-G) and estradiol-
17-glucuronide (E2-3-G), along with the parent molecules corticosterone (Cort) and 
estradiol (E2), caused TLR4 activation and/or potentiated pain responses when 
administered intrathecally.  We present the first evidence that the naturally occurring 
glucuronide metabolites E2-3-G and E2-17-G cause TLR4 activation in vitro and a potent 
TLR4-dependent pain response in vivo.  Additionally, each molecule tested, including 
Cort, CortG, and E2 as well as E2-3-G and E2-17-G, was predicted to dock to MD-2 in an 
in silico model utilizing a recently published TLR4-MD2 crystal structure (Park et al., 
2009). Further, the docking of each was altered when in silico modeling was repeated 
using an MD-2 structure with the TLR4 inhibitor (+)-naloxone already docked, indicating 
a (+)-naloxone sensitive docking. However, whether that interaction is as an antagonist or 
agonist to TLR4 signaling is unknown from the in silico docking alone.  An in vitro study 
using HEK cells transfected with TLR4 and necessary co-signaling molecules showed 
that E2-3-G and E2-17-G caused a dose-dependent increase in NFκB-dependent SEAP 
reporter gene protein expression.  Cort and E2, both in 1% DMSO vehicles, significantly 
reduced reporter gene protein expression relative to vehicle.  CortG produced no 
significant changes on TLR4 reporter protein.  When administered intrathecally, E2-3-G 
and E2-17-G caused a pain response that was blocked by the TLR4 antagonist LPS-RS.  
Cort, CortG and E2 did not cause a difference in pain sensation relative to their vehicles.   
 One inherent issue with Cort and E2 results is that, in addition to the potential for 
TLR4 activity, they also have potent effects on the glucocorticoid and estrogen receptors, 
respectively.  It is unknown whether CortG also acts on glucocorticoid receptors, while 
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E2-3-G and E2-17-G are not believed to have effects on estrogen receptors (Guillemette et 
al., 2004). The purpose of the present studies was to determine the potential of these 
drugs to cause TLR4 agonism, resulting in increased pain in a healthy in vivo model. 
Future studies might more directly assess the potential for TLR4 agonism independent of 
glucocorticoid or estrogen receptor function by coadministering glucocorticoid or 
estrogen receptor antagonists, or to assess the potential of these drugs as TLR4 
antagonists.  The present studies have not investigated potential dual roles for these 
compounds, in which the hormone receptor and TLR4 might cause opposing effects. 
 CortG is the first of six glucuronide metabolites tested in this methodology (Lewis 
et al., 2010a; Lewis et al., 2011a) that failed to either increase HEK-TLR4 cell reporter 
protein in vitro or cause potentiated pain responses in vivo.  One potential explanation is 
that, as discussed above, CortG may bind to glucocorticoid receptors.  Glucocorticoids 
are known to inhibit many inflammatory functions (Barnes, 2010), although in certain 
circumstances may also enhance LPS-induced inflammation (Frank et al., 2010).  As with 
Cort, this anti-inflammatory action may mask a potential TLR4 agonist effect.  Another 
possible explanation is that the structure of CortG is such that it lacks TLR4 agonism.  
Elucidating which explanation is correct will aid in the understanding of the nature of the 
TLR4 agonism in glucuronidated molecules. 
 The finding that estrogen metabolites can, by themselves, have TLR4-dependent, 
pain-producing effects has implications for several chronic pain disorders.  For instance, 
among women who suffer from migraines, about 60% are more likely to have a migraine 
during perimenstrual stage of their menstrual cycle, between ovulation and menses 
(Kornstein and Parker, 1997).  During this stage, there is a precipitous drop in circulating 
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estrogen levels. Notably, very high levels of estrogens, as in the third trimester of 
pregnancy, as well as very low levels of estrogens, as in post-menopause, both sharply 
reduce the risk of migraines (Craft, 2007).  The risk conferred during the perimenstrual 
stage, then, is not due exclusively to the level of estrogens, but rather due to the abrupt 
decline in circulating estrogens during this stage. A similar link between the 
perimenstrual stage and pain episodes was found in women suffering from 
tempromandibular joint disorder (LeResche et al., 2003).  The perimenstrual stage of 
estrogen withdrawal is also the period during which estradiol-glucuoronide 
concentrations will be maximal (Stanczyk et al., 1980; LeResche et al., 2003).  The 
studies here suggest that the TLR4 activation and enhanced pain caused by E2-3-G and 
E2-17-G could contribute to the increase risk, in women affected by the disorder, of 
menstrual migraine or tempromandibular joint pain in the perimenstrual period.  Were 
this link substantiated in future studies, it would create a novel treatment target in these 
challenging disorders. 
 These studies have shown that naturally produced steroid hormone metabolites, 
E2-3-G and E2-17-G are predicted to bind to MD-2 in silico, increase HEK-TLR4 cell 
reporter gene protein levels and cause TLR4-dependent pain. The finding that 
endogenously produced, naturally circulating molecules can have TLR4 effects is 
somewhat counterintuitive.  TLR4s are generally thought to detect danger signals, such as 
lipopolysaccharide from gram negative bacterial cell walls, indicative of bacterial 
invasion, and degraded membrane components that are not typically found 
extracellularly, indicative of tissue damage (Osterloh and Breloer, 2008).  While 
glucuronic acid, another endogenous molecule, has also been shown to activate TLR4 
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(Lewis et al., 2011a), it is typically found conjugated to form uridie diphosphoglucuronic 
acid or polymerized to form hyaluronan, rather than freely available.  We present the first 
evidence that an endogenously produced molecule can activate TLR4 and produce 
increased pain sensation. 
 There are several possible explanations for why TLR4 detects numerous 
compounds with a glucuronide component.  One, several classes of bacteria, such as 
streptococci, have a hyaluronan capsule surrounding their cell walls (Maclennan, 1956).  
Several studies have shown that TLR4 detects low molecular weight hyaluronan as the 
polymers degrade (Li et al., 2010; Leu et al., 2011). It is possible that the destruction of 
bacterial capsules and presence of low molecular weight hyaluronan became a danger 
signal of bacterial invasion, and one which was detected by TLR4.  Another potential 
explanation is that, while the chemical structure of the exogenously made estradiol 
glucuronide metabolites is identical to that produced endogenously, that other differences 
between endogenously and exogenously produced metabolites exist that result in the 
effects observed. All drugs tested free of endotoxin contamination on the LAL assay, one 
obvious concern, but there could be more subtle differences in the metabolism of these 
steroid hormones.  Finally, TLR4 is a pattern recognition receptor that responds to a 
range of molecular structures. While it evolved to detect danger signals, it is possible that 
it happens to detect a small number of molecules just by random chance. That is, 
molecules that are structurally similar to the danger signals detected by TLR4 also act as 
agonists without being danger signals themselves. 
 The studies here present evidence that the estradiol metabolites, E2-3-G and E2-
17-G, are predicted to bind to MD-2 in silico, increase the production of a HEK-TLR4 
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reporter protein in vitro and cause potent allodynia when administered intrathecally.  
Additionally, we determined that the parent molecules, Cort and E2 as well as the 
glucuronide metabolite CortG, are not TLR4 agonists in sum with other potential 
physiological effects.  These findings could have broad implications for migraine and 
other disorders, such as fibromyalgia and tempromandibular join disorder (Craft, 2007), 
in which female hormone levels have been linked to painful episodes. 
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ABSTRACT 
 We have previously demonstrated that both the opioid receptor antagonist (-)-
naloxone and the non-opioid active (+)-naloxone isomer antagonize toll-like receptor 4 
(TLR4) and can reverse neuropathic pain following chronic constriction injury in rats.  
The present studies expand on this finding to determine that (+)-naloxone was able to 
reverse a second model of neuropathic pain, spinal nerve ligation.  Further, (+)-naloxone 
was similarly effective 2 weeks after nerve injury and up to 4 months after nerve injury.  
Utilizing cell lines transfected with either TLR4 or TLR2, necessary co-signaling 
molecules and a reporter gene, the specificity of (+)-naloxone antagonism was tested.  
(+)-Naloxone successfully antagonized the increase in TLR4 reporter gene product 
caused by the classic ligand, lipopolysaccharide, but failed to antagonize the increase in 
TLR2 reporter gene product caused by the TLR2 agonist Pam3CSK4.  These studies 
provide additional evidence that supports the TLR4 antagonist (+)-naloxone as a novel 
candidate for the treatment of neuropathic pain. 
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Chronic neuropathic pain is extremely difficult to treat, with many patients 
gaining insufficient relief from existing treatments.  It is increasingly recognized that the 
proinflammatory molecules secreted by glial cells following nerve damage contribute to 
the establishment and maintenance of chronic neuropathic pain (Milligan and Watkins, 
2009).  However, there are currently no approved treatments that target this cellular 
response.  A potential target for developing therapeutics would be to reverse the ongoing 
activation of cells upstream of the production of proinflammatory cytokines, rather than 
the more common approach of blocking the effects of the proinflammaory cytokines. 
One mechanism proposed for the proinflammatory activation of glial cells in 
response to nerve injury is activation through toll-like receptor 4 (TLR4). TLR4 is a 
pattern recognition receptor that produces robust proinflammatory responses in cells 
when stimulated by its classic ligand, lipopolysaccharide (Lehnardt et al., 2003).  TLR4 
is found on, at least, microglia in the brain (Bsibsi et al., 2002) and has a complex 
signaling process involving a receptor complex, including CD14 and MD-2, and the 
activation of multiple downstream transcription factors (Dauphinee and Karsan, 2006). 
TLR4 signaling can be temporarily inhibited in a number of ways.  Two forms of 
inactive LPS, mutant LPS and LPS from Rhodobacter sphaeroides (LPS-RS), can 
competitively antagonize the LPS response. siRNA against TLR4 has also been show 
block the LPS response (Wu et al., 2010).  Finally, the small molecule antagonist 
naloxone can block TLR4 signaling (Hutchinson et al., 2008b; Hutchinson et al., 2010b).  
Notably, inhibition of TLR4 by all four methods has been shown to reduce the pain 
following sciatic nerve injury (Hutchinson et al., 2008b; Wu et al., 2010).  However, the 
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ability of TLR4 inhibition to reverse the pain caused by other models of neuropathic pain 
has not been tested. 
The antagonism of TLR4 signaling by naloxone is especially intriguing from a 
clinical perspective.  While siRNA and the large lipopolysaccharide molecules are unable 
to cross the blood-brain barrier, naloxone has well known CNS effects following 
systemic administration, making it a better candidate for pharmaceutical treatment of 
pain.  The best studied effects of naloxone are its ability to block opioid receptors.  
However, only the (-)-naloxone isomer antagonizes opioid receptors, while both the (-) 
and (+)-naloxone isomers have been shown to antagonize TLR4 and reverse neuropathic 
pain (Hutchinson et al., 2008b). (+)-Naloxone, then, is a blood-brain barrier permeable 
small molecule that has the ability to antagonize the TLR4 receptor without antagonizing 
the endogenous opioid system.  (+)-Naloxone has also been screened on a wide range of 
CNS targets with no known off-target effects (Northcutt et al., 2010). 
This series of studies seeks to further our understanding of the reversal of 
neuropathic pain by naloxone.  Specifically, we hypothesize that the ability of (+)-
naloxone to relieve neuropathic pain will generalize from the chronic constriction injury 
sciatic model (Hutchinson et al., 2008b) to a spinal nerve ligation model.  Additionally, 
we hypothesize that (+)-naloxone will be similarly effective at relieving neuropathic pain 
of long duration in both the spinal nerve ligation and sciatic nerve injury models.  Finally, 
we predict that (+)-naloxone will antagonize the LPS response on TLR4 signaling, but 
not the effect of a TLR2 agonist on TLR2 signaling, which would further indicate its 
specificity. 
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MATERIALS AND METHODS 
Subjects  
Adult, male, pathogen-free Sprague-Dawley rats (Harlan Labs, Madison, WI) 
were used Experiments 1, 2 and 5. Adult, male pathogen-free Sprague-Dawley rats 
(supplied by Laboratory & Animal Services, Waite Campus, University of Adelaide) 
were used in Experiment 3. Rats were 130-170 g at time of surgery in Experiments 1, 2, 
and 5; and 325-375 g at time of surgery in Experiment 3. Rats in both locations were 
housed in temperature (23±3 oC) and light (12 h:12 h light:dark) controlled rooms with 
water and food available ad libitum.  All habituation and behavioral testing procedures 
were performed during the light phase of the daily cycle.  Experimental procedures in 
Experiments 1, 2 and 5 were approved by the University of Colorado-Boulder 
Institutional Animal Care and Use Committee.  The experimental procedure in 
Experiment 3 was approved by the University of Adelaide Animal Ethics Committee.  
Each experimental group contains 6-9 rats. 
 
Drugs 
  (+)-Naloxone was obtained from the National Institute on Drug Abuse.  For in 
vivo studies, the toll like receptor 4 antagonist lipopolysaccharide (LPS) and the toll like 
receptor 2 antagonist Pam3CSK4 (Pam; Invivogen, San Diego, CA) were used. The 
vehicle for all drugs was sterile endotoxin free saline (Hospira, Lake Forest, IL).  (+)-
Naloxone, Pam and saline were confirmed to be endotoxin-free by the limulus amebocyte 
lysate assay (Lonza, Walkersville, MD), performed according to manufacturers 
instructions.  
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Spinal Nerve Ligation (SNL) 
 In Experiments 1, 2 and 5, neuropathic pain was induced through ligation of the 
5th and 6th lumbar spinal nerves, as described previously (Kim and Chung, 1992; Kim et 
al., 1997; Hutchinson et al., 2008b). Briefly, under isoflurane anesthesia, the left L5 and 
L6 spinal nerves were isolated and each nerve root tightly ligated with 6-0 silk suture. 
Sham controls had an identical surgery procedure except without the ligation of the spinal 
nerves. 
 
Chronic Constriction Injury (CCI) of the Sciatic Nerve 
 A second model of neuropathic pain used in Experiment 3 was the CCI model of 
partial sciatic nerve injury (Bennett and Xie, 1988).  CCI was performed at the mid-thigh 
level of the left hindleg as previously described (Milligan et al., 2004a).  In brief, under 
isoflurane anesthesia, the sciatic nerve was isolated and loosely tied with four sterile 
chromic gut sutures (4-0 chromic gut, Ethicon, Somerville, NJ, USA).   
 
Von Frey test for tactile allodynia 
All behavioral testing was conducted by an experimenter blind to group 
assignment. Rats received at least four 1 h habituations to the testing apparatus and 
environment prior to baseline testing, as in our previous studies (Lewis et al., 2010b). 
Baseline response thresholds were determined prior to nerve injury and rats tested 
periodically from 3 days post-injury until time of experiment. 
The response threshold to light touch on both plantar hind paws was measured 
using calibrated microfilaments (von Frey hairs; Stoelting, Wood Dale, IL, USA), as 
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described previously (Milligan et al., 2001).  Briefly, a logarithmic range of hairs from 
0.406-15.136 g force were used, allowing both analgesia and allodynia to be measured, 
following the standard up-down procedures previously described (Chaplan et al., 1994).  
Responses were fitted to a Gaussian integral psychometric function using a maximum-
likelihood fitting method as described previously (Milligan et al., 2001).  
 
In vitro assay for TLR4 signaling 
Two human embryonic kidney-293 (HEK 293) cell lines were used in Experiment 
5. One cell line was stably transfected by Invivogen (San Deigo, CA) to over-express 
human TLR4 and co-receptor molecules (MD-2, CD14) (referred to here as HEK-TLR4). 
The second cell line was stably transfected to overexpress human TLR2 (referred to here 
as HEK-TLR2; Invivogen, San Diego, CA).  In addition, both cell lines stably express an 
optimized alkaline phosphatase reporter gene under the control of a promoter inducible 
by transcription factors activated as part of the TLR2 and 4 signaling cascades. Secreted 
alkaline phosphatase (SEAP) protein is produced as a consequence of TLR4 activation.  
Both HEK-TLR4 and HEK-TLR2 cell lines were grown at 37oC (5% CO2; VWR 
incubator model 2300) in 10 cm dishes (Greiner Bio-One, CellStar 632171; Monroe, NC, 
USA) in normal supplement selection media (DMEM  media [Invitrogen, Carlsbad, CA, 
USA] supplemented with 10% fetal bovine serum [Hyclone; Logan, UT, USA], HEK-
TLR4 selecton [Invivogen]; Penicillin 10,000 U/ml [Invitrogen]; streptomycin 10 mg/ml 
[Invitrogen], Normocine [Invivogen], and 200 nM L-Glutamine [Invitrogen]).  The cells 
were then plated for 48 h in 96 well plates (Microtest 96 well plate, flat bottom, Becton 
Dickinson; 5 x 103 cells/well) with the same media. After 48 h, supernatants were 
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removed and replaced with fresh media.  Drugs tested were added in concentrations 
indicated and incubated for 24 h.  Supernatants (15 µl) were then collected from each 
well for immediate assay. 
SEAP levels in the supernatants were assayed using the Phospha-Light System 
(Applied Biosystems) according to the manufacturer’s instructions.  This 
chemiluminescent assay incorporates Tropix CSPD chemiluminescent substrate.  The 15 
µl test samples were diluted in 45 µl of 1x dilution buffer, transferred to 96-well plates 
(Thermo, Walthma, MA, USA), and heated at 65oC in a water bath (Model 210, Fisher 
Scientific, Pittsburgh, PA, USA) for 30 min, then cooled on ice to room temperature.  
Assay buffer (50 µl/well) was added and, 5 min later, reaction buffer (50 µl/well) is 
added and allowed to incubate for 20 min at room temperature.  The light output is then 
measured in a microplate luminometer (Dynex Technologies, #IL213.1191, Chantilly, 
VA, USA). 
 
Statistics 
 GraphPad Prism (version 5 for Windows, San Diego, CA) software was used for 
all statistical analyses. Two-way repeated-measures ANOVAs with Bonferroni post-hoc 
tests when appropriate were used to determine statistical significance between behavioral 
measures.  One-way ANOVAs with appropriate Bonferroni post hocs were used to 
compare experimental groups on in vitro experiments and to confirm that there were no 
baseline differences on behavioral measures. For all analyses, p<0.05 was considered 
significant. 
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Experimental Procedures 
Experiment 1: Does (+)-naloxone reverse neuropathic pain 2 weeks following SNL? 
 All rats underwent baseline (BL) von Frey testing followed by SNL surgery.  Two 
weeks following surgery, after robust and stable tactile allodynia had developed, rats 
were given 100 mg/kg (+)-naloxone subcutaneously (s.c.) or equivolume saline vehicle. 
Tactile thresholds were tested prior to and 1 and 3 hours following s.c. injection. 
 
Experiment 2: Does (+)-naloxone reverse neuropathic pain at 8 wk after SNL? 
 Two months post-SNL surgery, the efficacy of s.c. (+)-naloxone in increasing 
tactile thresholds was again tested.  Six rats used in Experiment 1 were used in this 
experiment, along with 6 sham rats from another, similar experiment.  All rats underwent 
BL von Frey testing and then SNL or sham surgery.  Beginning 8 weeks following 
surgery, rats were again assessed for their von Frey response and were then given (+)-
naloxone (100 mg/kg, s.c.) or equivolume saline vehicle in a counterbalanced within-
subjects design with a one-week washout period between injections. Tactile thresholds 
were assessed prior to and 1 and 3 hours following each s.c. injection. 
 
Experiment 3: Does (+)-naloxone reverse neuropathic pain 16 wk after CCI? 
 All rats underwent BL von Frey testing and then CCI surgery.  Four months later, 
(+)-naloxone (60 mg/kg, s.c.) or equivolume saline vehicle was given.  Tactile thresholds 
were assessed prior to and 30, 60, 90, 120 and 180 minutes following s.c. injection. 
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Experiment 4:  What is the dose-response function of (-)-naloxone on neuropathic 
SNL pain? 
 Rats underwent SNL surgery following BL von Frey testing.  Two weeks 
following surgery, as in Experiment 1, rats were given 1, 10 and 100 mg/kg doses of s.c. 
(-)-naloxone or equivolume saline vehicle in a within subjects design, starting with the 
lowest dose and with a one-week washout between doses.  Tactile sensitivity was 
assessed prior to and 1 and 3 h following each injection.   
 
Experiment 5: Does (+)-naloxone antagonize HEK-TLR4 or HEK-TLR2 cell SEAP 
expression? 
 HEK-TLR4 cells were stimulated with 0.1 ng/ml LPS to produce a robust 
increase in SEAP signal.  The efficacy of 1, 10 and 100 µM (+)-naloxone to inhibit the 
LPS signal was tested by coincubating each (+)-naloxone dose with 0.1 ng/ml LPS. 
Following a 24 h coincubation, supernatants were then assayed for SEAP expression.   
 Similarly, HEK-TLR2 cells were stimulated with 1 ng/ml Pam to produce a 
robust increase in SEAP signal of a similar magnitude to the LPS signal investigated in 
the HEK-TLR4 cells. The efficacy of 1, 10 and 100 µM (+)-naloxone to inhibit the Pam 
signal was tested by coincubating each (+)-naloxone dose with 1 ng/ml Pam. Following a 
24 h coincubation, supernatants were then assayed for SEAP expression. 
 
RESULTS 
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For all in vivo behavioral studies, no differences in tactile thresholds were 
detected between the ipsilateral and contralateral paws prior to or following drug 
administration; thus, results are reported as the average of both paws. 
 
Experiment 1: (+)-Naloxone reverses SNL-induced neuropathic pain. 
 Prior research has shown that (+)-naloxone (100 mg/kg) was sufficient to reverse 
allodynia induced by chronic constriction injury (CCI) (Hutchinson et al., 2008b).  In 
order to test whether the reversal of neuropathic pain generalized to another neuropathic 
pain condition, we utilized a spinal nerve ligation (SNL) model.  All rats developed 
significant allodynia following SNL. Fourteen days post SNL surgery, rats were given 
(+)-naloxone (100 mg/kg, s.c.) or equivolume saline.  There were no significant 
differences between groups in baseline tactile sensitivity (t=0.878, p>0.05) or the 
established allodynia prior to injection (t=0.774, p>0.05).  Baselines are lower than 
typically reported due to the particularly young and small rats used (~150 g at time of 
surgery). The (+)-naloxone dose significantly reversed the allodynia compared to saline 
controls (F=7.27, p<0.05, Figure 5.1), with post-hocs showing significant reversal at 1 
hour after injection.  
  
120
 
Figure 5.1.  (+)-Naloxone reverses SNL pain 2 weeks following injury.  There were no 
baseline differences between groups.  All rats developed significant allodynia following 
SNL surgery which was significantly reversed 1 h following 100 mg/kg s.c. dose of (+)-
naloxone. 
 
Experiment 2: (+)-Naloxone reverses long established SNL-induced neuropathic 
pain. 
 Long-established neuropathic pain can be more difficult to reverse than recently 
established neuropathic pain.  To test whether (+)-naloxone would be effective against 
long-established neuropathic pain, rats were given (+)-naloxone (100 mg/kg, s.c.) and 
equivolume saline vehicle 2 months following SNL or sham surgery in a within-subjects 
design.  There were no significant differences in baseline thresholds (t=1.80, p>0.05).  
(+)-Naloxone significantly reversed established allodynia in rats with SNL, but did not 
alter the tactile sensitivity of rats that underwent the sham surgery (F=19.2 p>0.05, 
Figure 5.2). 
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Figure 5.2. (+)-Naloxone reverses SNL pain 8 weeks following injury.  Rats with SNL 
surgery developed significant allodynia(Kim and Chung, 1992; Kim et al., 1997; 
Hutchinson et al., 2008b) while rats who underwent a sham surgery did not.  SNL-
induced allodynia was significantly reversed 1 h following 100 mg/kg s.c. dose of (+)-
naloxone, but saline vehicle did not significantly change SNL allodynia in this within-
subjects design. Neither (+)-naloxone nor saline altered the response thresholds of the 
rats who received sham surgery. 
 
Experiment 3: (+)-Naloxone reverses long established CCI-induced neuropathic 
pain. 
 Experiment 2 showed that (+)-naloxone was capable of reversing long-established 
SNL pain. To determine if this ability generalized to other neuropathic pain models, and 
in neuropathic pain of an even longer duration, rats 4 months post-CCI surgery were 
given (+)-naloxone (60 mg/kg) or equivolume saline vehicle.  In addition to determine if 
(+)-naloxone reverses long-established neuropathic pain in multiple models, the CCI 
model is better characterized long after initial injury (Milligan et al., 2006a; Milligan et 
al., 2006b).  A dose of 60 mg/kg was utilized to determine if a lower dose would also be 
effective.  There were no baseline difference between groups (t=0.05 p>0.05) and no 
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difference prior to injection.  (+)-Naloxone caused a significant reversal of CCI-induced 
allodynia (F=75.3, p<0.05. Figure 5.3).  Post-hoc tests showed a significant reversal at 
60, 90 and 120 minutes following injection. 
 
Figure 5.3.  (+)-Naloxone reversed CCI pain of 4 months duration.  There were no 
significant differences at baseline testing between groups.  All rats developed chronic 
allodynia following CCI surgery.  (+)-Naloxone (60 mg/kg, s.c.) significantly reversed 
allodynia 60, 90 and 120 minutes following injection.   
 
Experiment 4: (-)-Naloxone reverses neuropathic pain at 100 mg/kg but not at 10 
mg/kg. 
 Hutchinson et al. (2008b) demonstrated that a single 100 mg/kg (s.c.) dose of 
either (+)- or (-)-naloxone reversed neuropathic pain in a CCI model.  Experiment 1 
showed that the (+)-naloxone effect generalized to a second neuropathic pain model, SNL 
while Experiment 3 suggested that a lower dose of (+)-naloxone (60 mg/kg s.c.) was also 
effective.  In Experiment 4, the dose-response function for the (-)-naloxone reversal of 
SNL pain was determined using a within-subjects design. (-)-Naloxone, rather than (+)-
naloxone was chosen for study here for simplicity of being commercially available. This 
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choice was based on the fact that in vitro, in vivo (Hutchinson et al., 2008b), and in silico 
(Hutchinson et al., 2010b) tests indicate comparable effects of (+)- and (-)-naloxone on 
blockade of TLR4.  
All rats developed allodynia following SNL. There was a significant effect of 
drug (F=9.373, p<0.05), with post hoc tests showed (-)-naloxone significantly reversed 
allodynia at the 100 mg/kg dose, but not at the 10 or 1 mg/kg doses.  The magnitude of 
(+)- and (-)-naloxone reversal of SNL-induced allodynia was comparable, further 
evidence for the non-stereoselective nature of naloxone reversal of neuropathic pain. 
 
Figure 5.4. (-)-Naloxone significantly reversed SNL pain at a dose of 100 mg/kg, but not 
at lower doses.  All rats developed significant allodynia in this within-subjects design. 
 
Experiment 5: (+)-Naloxone antagonizes stimulated HEK-TLR4 cell SEAP 
expression, but not stimulated HEK-TLR2 cell SEAP expression. 
 Previous evidence suggests that (+)-naloxone can inhibit LPS-induced TLR4 
signaling (Hutchinson et al., 2008b).  Another TLR, TLR2, has been linked to similar 
proinflammatory responses to exogenous drugs.(Hutchinson et al., 2010a) TLR2, in fact, 
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shares cosignaling molecules with TLR4, such as MD2 (Dziarski and Gupta, 2000) and 
TIRAP (Yamamoto et al., 2002) as well as a similar downstream intracellular cascade 
(O'Neill, 2008).  Because the exact site of (+)-naloxone action is not yet known, it is 
conceivable that (+)-naloxone could inhibit TLR2 function given shared cell signaling 
steps.  To investigate whether (+)-naloxone is also a TLR2 inhibitor as well as a TLR4 
inhibitor, HEK-TLR4 and HEK-TLR2 cells were stimulated with a LPS or Pam, 
respectively, and the ability of (+)-naloxone to inhibit the agonist response measured.  
 In HEK-TLR4 cells (Fig. 5A), (+)-naloxone significantly inhibited the 
stimulation of LPS (F=112.3, p<0.05). Post-hoc tests showed that when 1, 10 and 100 
µM (+)-naloxone was coincubated with LPS, the SEAP expression was significantly 
reduced compared to LPS alone (Figure 5.5A).  In HEK-TLR2 cells (Fig. 5B), there was 
also a significant difference between groups (F=24.08, p<0.05). However, post hoc tests 
determined that neither 1, 10 nor 100 µM (+)-naloxone coincubated with Pam was 
significantly different from Pam alone (Figure 5.5B). The statistical significant 
differences were between Pam stimulated SEAP expression and vehicle or (+)-naloxone 
alone.  In summary, (+)-naloxone was able to block the HEK-TLR4 effects of LPS, but 
not the HEK-TLR2 effects of Pam.  
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Figure 5.5. (+)-Naloxone antagonizes stimulated HEK-TLR4 cell SEAP expression, but 
not stimulated HEK-TLR2 cell SEAP expression.  The increase in SEAP expression seen 
in LPS stimulated HEK-TLR4 cells was significantly blocked by coincubation with 1, 10 
or 100 µM (+)-naloxone.  The increase in SEAP expression caued by Pam in HEK-TLR2 
cells was unaffected by coincubation with 1, 10 or 100 µM (+)-naloxone. 
 
DISCUSSION 
The studies presented here expand our knowledge of the TLR4 antagonist (+)-
naloxone and its ability to reverse neuropathic pain behaviors.  The ability of (+)-
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naloxone to reverse neuropathic pain in models beyond chronic constriction injury (CCI) 
was tested using a spinal nerve ligation (SNL) model of neuropathic pain.  (+)-Naloxone 
successfully reduced SNL-induced allodynia 1 hour following subcutaneous injection, 
indicating that (+)-naloxone was effective on multiple models of neuropathic pain.  We 
also present the first evidence that (+)-naloxone can reverse longstanding neuropathic 
pain.  (+)-Naloxone reversed the allodynia expressed either 2 months following SNL or 4 
months following CCI.  Given the success of (+)-naloxone in reversing neuropathic pain, 
and prior observation that (+)-naloxone and (-)- naloxone produce comparable reversal of 
CCI-induced neuropathic pain (Hutchinson et al., 2008b), we conducted a dose-response 
study on  the commercially available (-)-isomer of naloxone for its ability to reverse 
SNL-induced allodynia.  The effective dose of (-)-naloxone was 100 mg/kg.  Hence, as 
with CCI-induced pain (Hutchinson et al., 2008b), (-)-naloxone was similarly effective to 
(+)-naloxone in reversing SNL pain at the 100 mg/kg dose confirming the 
nonstereoselective nature of naloxone’s effect.  Finally, utilizing HEK cells transfected 
with either TLR4 or TLR2 and necessary co-signaling molecules, the ability of (+)-
naloxone to inhibit TLR4 and TLR2 signaling was tested.  (+)-Naloxone inhibits LPS-
induced increases in TLR4 reporter protein, but did not affect Pam-induced increase in 
TLR2 reporter protein, further evidence of its specificity as a TLR4 inhibitor. 
The effectiveness of (+)-naloxone in reversing neuropathic pain up to 4 months 
after nerve injury provides additional support for a role of TLR4 in perpetuating 
neuropathic pain.  Previous work has shown that both TLR4 knockout and co-receptor 
CD14 knockout mice developed reduced analgesia and hyperalgesia following L5 spinal 
nerve transaction (Tanga et al., 2005; Cao et al., 2009).  Additionally, siRNA blockade of 
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TLR4 given at time of surgery was also able to reduce the development of CCI 
neuropathic pain (Wu et al., 2010).  However, the ability of (+)-naloxone to reverse 
neuropathic pain, as shown here and in Hutchinson et al.(2008b), as well as the ability of 
mutant LPS and LPS-RS to reverse neuropathic pain (Hutchinson et al., 2008b) suggest 
that TLR4 is being continually stimulated during these neuropathic pain conditions. 
Given the role of TLR4 in ongoing neuropathic pain, it is a potential target for 
novel pharmaceutical treatment.  TLR4 is principally found on microglia in the central 
nervous system (Bsibsi et al., 2002), but has been shown to be upregulated on neurons 
following ischemic injury (Tang et al., 2007).  When activated, it leads to the 
upregulation of several MAPKs and activation of the transcription factor NFκB 
(Dauphinee and Karsan, 2006).  Ultimately, TLR4 activation can lead to the production 
and release of proinflammatory cytokines, including interleukin-1β and tumor necrosis 
factor-α (Dauphinee and Karsan, 2006).  (+)-Naloxone has previously been shown to 
reduce the production of proinflammatory cytokines in vitro and reduce the microglial 
activation marker CD11b in vivo (Hutchinson et al., 2008b).  This finding suggests that 
glial activation inhibition and reduced proinflammatory cytokine production are potential 
mechanisms for (+)-naloxone reversal of neuropathic pain.  Notably, other compounds 
that reduce proinflammatory cytokine production and reduce microglial cell activation 
have also been shown to be effective against neuropathic pain in rodent models 
(Ledeboer et al., 2005; Ledeboer et al., 2006). 
(+)-Naloxone provides a blood-brain barrier permeable, small molecule, TLR4 
antagonist that reverses neuropathic pain in multiple models, months after onset, making 
it an intriguing potential treatment.  While (-)-naloxone is similarly effective on 
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neuropathic pain, it has the disadvantage of also inhibiting the endogenous opioid system, 
which reduces its applicability.  One limitation of (+)-naloxone is its short time of effect.  
The effect of s.c. (+)-naloxone lasted less than 3 hours here and in prior studies 
(Hutchinson et al., 2008b).  One potential candidate to improve upon the pain reversal of 
(+)-naloxone is (+)-naltrexone.  (+)-Naltrexone is a small molecule that, similar to (+)-
naloxone, is the non-opioid active isomer of the opioid receptor antagonist (-)-naltrexone.  
In humans, naltrexone has a half life of about 4 hours, significantly longer half-life than 
the 1-1.5 hour half-life of naloxone, and is also blood-brain barrier permeable (Dawson, 
2004).  (+)-Naltrexone antagonizes the LPS-induced increase in HEK-TLR4 cell reporter 
gene expression, reverses neuropathic pain behaviors when given intrathecally 
(Hutchinson et al., 2008b), and docks to MD-2 in silico (Hutchinson et al., 2010b).  
However, the lack of commercial availability is a serious impediment to investigating the 
effects of both (+)-naloxone and (+)-naltrexone and several key studies have not yet been 
performed due to limited availability of the compounds.  
Current evidence suggests that (+)-naloxone is relatively specific to the TLR4 
receptor.  In a screen of central nervous system targets other than TLR4, including 
neuronal neurotransmitter receptors, hormone receptors, and enzymes, (+)-naloxone did 
not have a significant binding affinity to any target (Northcutt et al., 2010).  Here, we 
show that (+)-naloxone also did not affect Pam-induced TLR2 activation.  Currently, no 
known off-target effects of (+)-naloxone exist; however, additional screening of immune 
system targets would be informative.  A lack of off-target effects decreases the chances 
that (+)-naloxone will have negative side effects.  Additionally, (-)-naloxone has been 
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used clinically for years to reverse opioid actions, such as respiratory depression, with a 
good safety profile. 
Chronic neuropathic pain is a widespread condition that often remains resistant to 
current treatments.  Reduced TLR4 signaling has been shown to reduce neuropathic pain 
behaviors in rats in these studies and others (Tanga et al., 2005; Hutchinson et al., 2008b; 
Cao et al., 2009; Wu et al., 2010).  (+)-Naloxone, an orally available, blood brain barrier 
permeable small molecule, has been shown here to reverse neuropathic pain two weeks to 
four months after the onset of pain.  (+)-Naloxone antagonizes TLR4 signaling and has 
no known off-target effects, having demonstrated no TLR2 inhibitory effects here, no 
opioid receptor activity (Iijima et al., 1978), and no binding affinity in a screen of CNS 
targets (Northcutt et al., 2010).  The effectiveness of (+)-naloxone on neuropathic pain, 
ease of administration and existing safety record in clinical settings make it an intriguing 
compound for future study. 
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CHAPTER 6 
DISCUSSION 
 
The studies here have advanced our knowledge of the role of TLR4 in acute and 
chronic pain states. We have demonstrated that a group of TLR4 agonists, glucuronide 
metabolites, transiently enhance pain behaviors when given intrathecally, an effect 
blocked by the TLR4 antagonist LPS-RS.   The finding that many glucuronide 
metabolites can act on TLR4 suggests that they be considered more carefully in drug 
development than is currently the standard.  Additionally, it suggests that glucuronide 
metabolites be considered as contributors to well known side effects of the parent drugs.  
The opioid-inactive (+)-naloxone, shown here to reverse multiple models of neuropathic 
pain, is a blood-brain barrier permeable TLR4 signaling inhibitor.  (+)-Naloxone also 
blocked morphine-3-glucuronide-induced pain behaviors, suggesting it may be a 
candidate compound to mitigate the TLR4-dependent pain enhancement of these 
glucuronide metabolites.  Finally, these glucuronide studies combined to develop an 
approach for testing TLR4 agonism in vitro and predicting pain behaviors in vivo. 
 
I.  TLR4 in Pain States 
 Traditionally, researchers and regulatory agencies alike have considered the 
majority of glucuronide metabolites as biologically inert (Davis-Bruno and Atrakchi, 
2006).  In the survey here of 6 different glucuronide compounds, including opioid, steroid 
hormone and alcohol metabolites, 5 were found to produce TLR4-dependent pain 
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following intrathecal injection.  These data suggest that glucuronidation should be 
considered as a potential bioactivation step, with TLR4 agonism as a possible result.  A 
thorough study of morphine-3-glucuronide (M3G) showed that it caused this enhanced 
pain through increased proinflammatory cytokine production, a common end product of 
TLR4 activation and a likely mechanism for pain enhancement. 
 Prior studies of exogenous drugs that activate TLR4 have been necessarily 
confounded by dual actions of TLR4 signaling and the target drug effects (Hutchinson et 
al., 2010a; Hutchinson et al., 2010b).  However, several of the glucuronide metabolites 
tested, including glucuronic acid (GA), ethyl glucuronide (EtG) and the estradiol 
glucuronides (E2-3-G, E2-17-G), lose their activity at the site of parent drug action, 
leaving TLR4 as the only known receptor on which they can act.  The finding of a 
potential mechanism for drug side effects that is separate from the parent drug site of 
action presents the intriguing possibility that one could block the side effects without 
reducing the drug’s efficacy. 
 Notably, for all of the parent drugs whose metabolites were found to produce 
TLR4-dependent pain, including morphine, ethanol and estradiol, the withdrawal of the 
parent drug can trigger various states of enhanced pain. Withdrawal from chronic 
morphine has long been associated with a hyperalgesia, which has recently been linked to 
an increase in proinflammatory signaling (Raghavendra et al., 2004b). Withdrawal from 
both acute (Howland et al., 2008) and chronic (Jochum et al., 2010; Martinotti et al., 
2010) alcohol can cause headaches and other hypersensitivities.  And the period of 
declining estradiol in menstruating females is the period of greatest risk for migraine 
(Kornstein and Parker, 1997), temporomandibular joint pain (LeResche et al., 2003) and 
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other pain disorders.  For each of these diverse drugs, the period of drug withdrawal will 
is the time when glucuronoide metabolites are in highest concentration relative to the 
parent drug (Stanczyk et al., 1980; Droenner et al., 2002; LeResche et al., 2003; Dale et 
al., 2007). While numerous neuronally-based mechanisms have been postulated for these 
withdrawal symptoms, the findings of these studies suggest metabolites and TLR4 
signaling should be considered as an additional hypothesis.  Were such a hypothesis 
substantiated, it would provide a novel avenue for treating these hyperalgesic effects, that 
of TLR4 signaling inhibition and/or glial inhibition. 
The opioid-inactive (+)-naloxone isomer, in addition to its ability to reverse 
multiple models of chronic neuropathic pain (Lewis et al., 2011c), was also able to 
reduce the hyperalgesia and allodynia produced by M3G.  This suggests that (+)-
naloxone, shown to be a TLR4 signaling inhibitor in numerous different situations 
(Hutchinson et al., 2008b; Hutchinson et al., 2010b; Lewis et al., 2011b), might be an 
effective co-treatment with molecules known to produce glucuronide sensitivities in 
addition to its potential as an effective treatment for neuropathic pain. 
 
II. Method for screening TLR4 agonists 
 The studies presented here provide further evidence that TLR4 activation can 
contribute to enhanced pain.  Numerous exogenous drugs were shown to activate TLR4 
and cause enhanced pain. One useful application of these studies is the development of a 
screening procedure for potential TLR4 agonists that may have the potential to enhance 
pain. 
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 HEK-TLR4 cells are transfected with TLR4 and necessary co-signaling 
molecules, along with an NFκB-dependent SEAP reporter gene.  An increase in NFκB 
activation following TLR4 signaling leads to an increase in SEAP gene expression.  
HEK-TLR4 cells SEAP expression in these studies can predict the amount of pain that 
develops following intrathecal injection (Figure 6.1).  All intrathecal injections were 
equimolar.  There was a significant correlation between HEK-TLR4 cell NFκB-
dependent SEAP expression and the degree of pain induced (r2=0.72, p<0.05).  HEK-
TLR4 cell SEAP expression induced by 100 µM concentration of drug predicted the 
amount of pain that developed 3 hours following intrathecal injection.  All measures are 
reported as percent vehicle in order to have a meaningful comparison between 
compounds with different solubility requirements. 
 
Figure 6.1  The degree of HEK-TLR4 cell NFκB-dependent SEAP expression predicts 
the degree of pain induced by the compound. 
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 Previous papers have been able to predict agonist activity in the HEK-TLR4 cell 
assay based on an in silico docking model similar to that undertaken here (Hutchinson et 
al., 2010a; Hutchinson et al., 2010b).  The present studies were not able to predict HEK-
TLR4 SEAP expression or pain behaviors based on a simple correlation to the in silico 
predicted docking energy. However, the present studies investigated glucuronide 
metabolites from a range of different drug classes, unlike the previous papers which 
investigated either opioid or tricyclic compounds, respectively.  This limited the 
complexity of the model that could be developed.  Additionally, the molecules in the 
present studies were tested strictly for agonism at TLR4, not antagonism, so certain 
molecules that were predicted to dock to MD-2 in silico, but failed to enhance HEK-
TLR4 SEAP expression or pain, may in fact be TLR4 signaling antagonists.  It is likely 
that a more detailed in silico analysis utilizing molecules structurally related and a more 
complex model would successfully predict in vitro TLR4 agonism. 
 Another question is whether the effects of the glucuronide metabolites are due 
exclusively to the glucuronic acid (GA) component, or whether they are enhanced by the 
presence of the parent drug group.  GA and the structurally similar ethyl glucuronide had 
nearly identical performance on both the intrathecal injection pain behavior test and the 
HEK-TLR4 cell assay.  M3G and E2-3-G both had somewhat greater HEK-TLR4 cell 
SEAP expression, but pain behavior was near the floor of our testing abilities such that, 
were there a real decrease in pain thresholds relative to GA, our test may not have been 
able to detect it.  Notably, CortG didn’t induce any pain behavior at all.  A glucuronide 
group alone does not seem to confer TLR4 activity, and the results are inconclusive as to 
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whether the parent drug conformation contributes to the degree of HEK-TLR4 SEAP 
expression and pain behavior. 
 
III. Potential implications and future directions 
 Although glucuronidation is largely considered a deactivating step, one class of 
glucuronide metabolites, the acyl glucuronides, has previously been linked to negative 
side effects, including immunogenicity (Bailey and Dickinson, 2003).  Acyl glucuronides 
are derived from compounds with a carboxylic group, including the common nonsteroidal 
anti-inflammatory drugs naproxen and ibuprofen. Both naproxen and ibuprofen have 
been linked to hypersensitivity reactions, including rash, fever and immunocytopenia, in 
a small subset of users (Bailey and Dickinson, 2003).  The findings here suggest that the 
glucuronide metabolites of these drugs be considered as potential contributors to these 
rare, immogenic hypersensitivity reactions.   Additionally, other classes of glucuronide 
metabolites, including the acyl glucuronides and drug classes with negative side effects 
associated with withdrawal of drugs, should be tested for potential TLR4 signaling and/or 
proinflammatory responses in the CNS.  
 The survey of glucuronide metabolites was not designed to determine which cell 
types were involved, only to determine if TLR4 was a component. As TLR4 can be 
expressed on most of the major cell types in the CNS, the exact mechanism is not known.  
The finding of TLR4 involvement in many of these metabolites suggests that a more in-
depth study of mechanisms and cell types, similar to that performed for morphine-3-
glucuronide, would be fruitful.  Additionally the finding of increased proinflammatory 
response in cerebrospinal fluid and lumbar dorsal horn in M3G suggest that a more 
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detailed analysis of the proinflammatory response to other glucuronide metabolites is 
warranted. 
 
IV.   Conclusions 
 This dissertation expanded on the knowledge of TLR4 signaling in pain states.  
We present the first evidence that a group of molecules, conjugated glucuronide 
metabolites, can induce TLR4 activity and TLR4-dependent acute pain sensitization.  
Specifically, glucuronic acid, morphine-3-glucuronide, ethyl glucuronide, estradiol-3-
glucuronide and estradiol-17-glucuronide were all found to enhance TLR4 signaling in an 
in vitro model and to cause pain sensitization in vivo that was blocked by the TLR4 
antagonist LPS-RS.  This finding has broad potential implications for these metabolites to 
contribute to parent drug effects.  In particular, withdrawal from morphine, alcohol and 
estradiol is associated with an increase in pain sensation, and also corresponds to the time 
of highest glucuronide metabolite concentrations.  These findings further suggest that 
glucuronidation be considered a bioactivation step with the potential to produce active 
metabolites with TLR4 activity. 
 This work also increased our understanding the role of (+)-naloxone, a TLR4 
signaling inhibitor with no known off-target effects.  (+)-Naloxone is a orally available 
blood-brain barrier permeable small molecule, making it of greater pharmaceutical 
potential than other larger, non blood-brain barrier permeable options.  Building on the 
work of Hutchinson et al. (2008b), (+)-naloxone was found to reverse multiple models of 
neuropathic pain, up to 4 months following initial nerve injury.  This finding also 
suggests an ongoing role for TLR4 long after the establishment of neuropathic pain.  (+)-
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Naloxone was also found to block the enhanced pain following intrathecal M3G 
injection, suggesting it may also have applications for reducing the effects of glucuronide 
metabolites. 
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